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Interstitial lung disease (ILD) and its associated treatments have the potential to put 
patients at nutrition risk. However, minimal is known about the relationship between 
nutritional status on disease severity and prognosis in ILD. Existing research is limited by 
its focus on weight and body mass index (BMI). Therefore, the primary objective of this 
cross-sectional, prospective study was to determine the prevalence of malnutrition using 
the subjective global assessment (SGA) and to estimate body composition using 
bioelectrical impedance analysis (BIA) among individuals with ILD (n = 78). A second 
objective of this research was to investigate the appropriateness of bioimpedance 
parameters such as standardized phase angle (SPhA) and impedance ratio z-score (z-IR) 
as surrogate markers of malnutrition. The third objective of this research was to evaluate 
how nutrition status and body composition are related to functional exercise capacity 
using 6-minute walk distance (6MWD). The fourth objective explored the relationship 
between fat-free mass index z-score (z-FFMI) and body fat mass index z-score (z-BFMI), 
body composition measures which are controlled for age and sex, and nutrition status, 
with survival. Results indicate that most participants were mildly malnourished (49%). 
Additionally, 11.5% of patients had normal body composition, 20.5% were classified as 
sarcopenic, 60% were obese and the remaining 8% were classified as sarcopenic obese. 
z-FFMI and SGA were significantly associated with exercise capacity independent of 
lung function. Low BMI, z-FFMI and z-BFMI were associated with severe malnutrition. 
SPhA did not correlate with nutrition status, however, increased z-IR significantly 
increased the odds of severe malnutrition.  Age, BMI, z-FFMI, z-BFMI, exercise 
capacity, disease severity, and severe malnutrition were significant predictors of survival. 
z-FFMI and severe malnutrition were significantly associated with survival independent 
of disease severity. These results are sufficiently encouraging to warrant further research 
into the nutritional status of ILD patients. Future research should assess if nutrition 
interventions can improve fat-free mass and functional exercise capacity in patients with 
ILD.  Assessment of fat-free mass should be considered alongside or in place of BMI as a 
nutritional variable when analyzing survival risk in ILD patients as it can better identify 
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Summary for Lay Audience 
Interstitial lung disease (ILD) and its treatments put patients at risk of poor nutrition. 
However, little is known about the link between nutrition and ILD, nor about the 
influence of nutrition on survival in patients with ILD. Most ILD nutrition research has 
focused on weight and body mass index (BMI). Therefore, the primary objective of this 
study was to determine how common malnutrition is in ILD patients using the subjective 
global assessment (SGA), and to estimate body composition (lean body mass and body 
fat) using bioelectrical impedance analysis (BIA) among 78 individuals diagnosed with 
ILD. A second objective of this research was to investigate if suspected markers of 
nutrition status, such as, standardized phase angle (SPhA) and impedance ratio z-score (z-
IR) measured using BIA, can be used to accurately identify malnutrition. The third 
objective of this research was to explore how nutrition status and body composition are 
related to exercise capacity, using 6-minute walk distance (6MWD). Lastly, the fourth 
objective explored the relationship between body composition and nutrition status with 
survival. A large portion of the patients were mildly malnourished (49%). Lean body 
mass controlled for age, sex and height, and nutrition status were significantly associated 
with exercise capacity regardless of the severity of ILD. Low BMI, low muscle mass and 
low body fat were associated with severe malnutrition. z-IR, but not SPhA, was 
associated with severe malnutrition. Age, BMI, lean body mass, body fat, exercise 
capacity, disease severity and severe malnutrition predicted survival in ILD patients. 
Muscle mass controlled for age, sex and height, and severe malnutrition predicted 
survival regardless of disease severity. These results justify future exploration into the 
nutritional status of ILD patients which can be used to develop individualized nutrition 
care plan for patients with ILD. Future research should assess if nutrition interventions 
can increase muscle mass and/or exercise capacity. When possible, muscle mass should 
be measured along with or in place of BMI as it can better identify those at risk of death 
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Chapter 1  
1  Introduction 
 Background 
We take roughly 20,000 breaths each day, most of which we take no notice. However, for 
most people it is not until breathing becomes a struggle, that it becomes obvious how 
profound an impact the ability to breathe has on daily life. Interstitial lung disease (ILD) 
comprises a heterogeneous range of chronic lung disorders which involve irritation and 
swelling of the tissue lining the lungs making it difficult to breath (Bradley et al. 2008; 
Cottin et al. 2019). ILD is associated with significant morbidity and mortality as survival 
after diagnosis of some ILDs is only 2.5 to 5 years (Richeldi et al. 2003). The 
management strategy of ILD includes home oxygen  (Crockett, Cranston, and Antic 
2001), pulmonary rehabilitation (Holland and Hill 2008; Nakazawa, Cox, and Holland 
2017), and weight optimization (Alakhras et al. 2007). However, little is known about the 
relationship between nutritional status and clinical course of ILD, a potentially important 
implication on the outcome and quality of life of these patients.  
Ample research indicates that ILD, its treatments and medication side-effects put patients 
at nutrition risk (Quinn, Wisse, and Manns 2019; Trawinska, Rupesinghe, and Hart 
2016). However, little is known about the relationship between nutritional status and 
disease severity or prognosis in ILD patients. Existing research is limited by its focus on 
weight and body mass index (BMI), and overlooks the components of body mass; fat-free 
mass and body fat mass. Nutrition intervention can have a significant impact on clinical 
outcomes such as improved quality of life and better tolerance to medical treatments 
(Charney 2008). No nutrition recommendations are included in ILD best practice 
guidelines (Raghu et al. 2015; Travis et al. 2013). Research using gold standard and well-
accepted clinical assessment tools is needed to determine the prevalence of malnutrition 
and body composition concerns, such as inadequate fat-free mass, in ILD patients. 
Addressing this research gap will help to establish best practice guidelines to be used by 





At present, nutrition professionals such as registered dietitians (RDs) are not part of the 
standard of care of ILD patients. For many, it is not until their disease has significantly 
progressed that an RD may become involved in their care. For example, this may occur 
due to a hospitalization or lung transplant assessment. For those individuals that require 
lung transplantation assessment, this may be the first involvement of a RD in their care, 
and the RD’s involvement is generally focused on weight management. As many ILD 
patients are overweight or obese (Alakhras et al. 2007), therefore, weight loss may be 
required to meet BMI cut-offs in order to receive a lung transplant. However, at this point 
in their disease, many barriers, such as reduced exercise capacity (energy output) and 
increase appetite secondary to medication use (energy input), make weight loss very 
difficult to achieve. Additionally, due to disease exacerbations patients may end up in 
hospital. Although, inpatient RD involvement can help address nutrition issues, that is if 
the inpatient RD is referred to ILD patients in the first place, the hospital setting itself can 
contribute to further malnutrition in these patients. Specifically, even just 1-week of bed 
rest can lead to substantial loss of muscle mass and strength (Dirks et al. 2016) resulting 
in patients leaving hospital deconditioned. Without adequate supports to address loss of 
muscle mass post-hospital admission, this further contributes to the progressive loss of 
functional capacity and risk of malnutrition in ILD patients.   
Diminished exercise capacity in ILD is multifaceted with pathophysiological factors such 
as impaired gas exchange in the lungs, altered respiratory mechanics, limited pulmonary 
circulation and peripheral muscle dysfunction (Holland et al. 2008; Raghu et al. 2011). No 
studies have explored the influence of poor nutrition status on diminished exercise capacity 
in ILD. Clinical nutrition research is needed to determine if a relationship exists between 
nutrition status and exercise capacity as this would provide justification for future research 
into nutrition intervention as a non-exercise component in pulmonary rehabilitation 
programs (Nakazawa, Cox, and Holland 2017).  
The subjective global assessment (SGA) is the gold standard of nutrition assessment which 
evaluates nutritional status subjectively. Phase angle (PhA), an indicator of cell health, is 
obtained using bioelectrical impedance analysis (BIA) and is strictly an objective measure. 





measurement is a simple and non-invasive bedside technique. Research focused on the 
utility of PhA as a surrogate marker of malnutrition has a low evidence quality (Rinaldi et 
al. 2019). However, at present research is limited to only four disease states. The use of 
PhA in nutrition assessment in disease has not been validated, therefore, more extensive 
research in a variety of disease states, including ILD, is needed(Rinaldi et al. 2019)(Rinaldi 
et al. 2019)(Rinaldi et al. 2019)(Rinaldi et al. 2019)(Rinaldi et al. 2019).  
It has been suggested that increased BMI is correlated with an increased survival in ILD 
(Alakhras et al. 2007). However, this reverse epidemiological effect of increased BMI fails 
to recognize the important contribution of fat-free mass to health. ILD research has only 
recently focused on fat-free mass as a promising predictor of survival (Nishiyama et al. 
2017). Having identified fat-free mass as an important component of survival, it is pertinent 
that research focused on how specific components of body weight, specifically fat-free 
mass and body fat mass, influence survival in ILD continues. This area of research may 
directly benefit ILD patients through improving the prognosis of their disease.  
 Research Purpose and Objectives of the Research 
The overarching purpose of this dissertation research is to gain a better understanding of 
nutritional concerns in ILD patients. Related to this purpose, this dissertation intends to 
meet the following four research objectives. 
1) The first objective of this research was to determine the prevalence of malnutrition using 
the gold standard of nutrition assessment, subjective global assessment (SGA), and to 
estimate body composition (fat-free mass index (FFMI) and body fat mass index (BFMI)) 
using BIA, among individuals with ILD.   
2) The second objective of this research was to evaluate how nutrition status and body 
composition are related to functional exercise capacity using 6-minute walk distance 
(6MWD).  
3) The third objective of this research was to investigate the utility of bioimpedance 
parameters controlled for age, sex and/or BMI, such as 50 kHz PhA and 200/5 kHz 





4) The fourth objective was to examine whether FFMI and BFMI controlled for age and 
sex, and nutrition status were independent predictors of survival in ILD patients.  
 Study Area and Population  
ILD typically affects middle-aged and older adults, with approximately two-thirds of 
patients being 60 years and older at time of presentation of ILD (Kim 2006). The primary 
population for this dissertation research was adults 18 years and older who were diagnosed 
with ILD.  Participants were recruited from one respiratory clinic taking place at London 
Health Sciences Centre, Victoria Hospital in London, Ontario.  
 Outline of Dissertation 
This dissertation is formatted in an integrated article approach. In the following chapters, 
this dissertation addresses these four objectives. Following this introduction, Chapter 2 
provides a literature review on background information relevant to these objectives 
including disease background, nutrition-related knowledge to date in ILD including a 
review of BIA and bioimpedance surrogate markers of nutrition status, nutrition-related 
concerns with ILD medication use, and exercise capacity.  
A literature review continues through Chapter 3 with a published review article on the 
gold standard method of nutrition assessment, SGA, as well as, PhA, a measure of cell 
health obtained using BIA. PhA is theorized to be an objective measure of nutrition status. 
This published review assesses the literature on SGA and PhA, and critically reviews the 
quality of evidence supporting PhA as a surrogate measure of nutrition status.   
Chapter 4 specifically addresses the first three objectives of this dissertation; 1) to 
determine prevalence of malnutrition and estimate body composition measures in ILD 
patients, 2) to evaluate how nutrition status and body composition are related to functional 
exercise capacity and 3) to determine the appropriateness of bioimpedance parameters to 





Chapter 5 addresses the fourth objective to examine whether nutrition status, and FFMI 
and BFMI, controlled for age and sex, are independent predictors of survival in ILD 
patients.  
Lastly, Chapter 6 provides overall conclusions including the contributions to research, 
clinical implications and recommendations, challenges and limitations of this thesis 






Chapter 2  
2 Literature Review – Part I 
Nutrition-Related Concerns in Interstitial Lung Disease  
This literature review is organized into two parts. This chapter concentrates on nutrition-
related concerns in interstitial lung disease (ILD). The second part of the literature review, 
found in Chapter 3, is a published systematic review focused on assessing phase angle 
(PhA) as a surrogate marker of nutrition using Subjective Global Assessment (SGA) as the 
reference standard.  
This chapter first provides a review of ILD etiology, prognosis and disease management 
before turning to a review of the various nutrition-related concerns affecting ILD patients, 
including body weight, body mass index (BMI), body composition concerns, nutrition-
related side effects associated with ILD medications, and functional exercise capacity as it 
relates to nutrition status. Overviews of bioelectrical impedance analysis (BIA) and 
bioimpedance surrogate markers of nutrition status which were used in this research are 
also integrated in this section to provide appropriate background and context for the 
discussed nutrition and ILD focused literature.   
 Interstitial Lung Disease 
2.1.1 Etiology  
Interstitial lung disease comprises a heterogeneous range of chronic lung disorders which 
cause various degrees of inflammation or fibrosis in the pulmonary parenchyma including 
the alveoli, trachea, bronchial tree, or blood vessels, and/or pleura (Bradley et al. 2008; 
Cottin et al. 2019). One of the most common ILDs is idiopathic pulmonary fibrosis (IPF). 
IPF is characterized by progressive fibrosis and architectural distortion of the lining of the 
air sacs of the lungs, or alveoli, and is relentlessly progressive (Raghu et al. 2018). Other 
fibrotic ILD subtypes include connective tissues disease-associated ILD, idiopathic 
nonspecific interstitial pneumonias and chronic hypersensitivity pneumonitis (Ryerson et 
al. 2016).  While the etiology of some ILDs, including IPF, remains unknown (Travis et 





toxicities, or are secondary to CTD (Bradley et al. 2008). Reports of the incidence of ILD 
subtypes is limited by the broad range of ILD and the rarity of some ILD subtypes (Olson 
et al. 2018). In 2011, IPF affected 42 in 100,000 Canadians, of which the prevalence of IPF 
was greater in males than females and drastically increased with advancing age (Hopkins 
et al. 2016). As many ILDs are rare, recognizing and diagnosing specific subtypes require 
considerable expertise.  
2.1.2 Prognosis   
The clinical course and outcome of ILD are highly variable between different subtypes 
(Bradley et al. 2008), however, in general, ILD is associated with significant morbidity and 
mortality (Richeldi et al. 2003). In IPF, survival after diagnosis is only 2.5 to 5 years in the 
absence of treatment (Collard et al. 2003; Mura et al. 2012).  Prognosis varies among and 
within disease subtypes, and by a variety of clinical and demographic parameters. 
Epidemiological data such as advancing age, male sex, and clinical features such as 
symptoms of dyspnea are reliable predictors of survival at diagnosis of IPF (Fernández 
Fabrellas et al. 2018). Clinical markers such as abnormal pulmonary function tests, 6-
minute walk distance (6MWD), dyspnea scores and BMI can help predict survival in ILD 
(Alakhras et al. 2007; Collard et al. 2003; Manali et al. 2008). Specific clinical parameters 
such as percent predicted diffusing capacity for carbon monoxide (%DLco) ≤ 40% at the 
time of diagnosis, or a decline in %DLco or percent predicted forced vital capacity (%FVC) 
overtime can predict survival in IPF (Fernández Fabrellas et al. 2018). A decline in %FVC 
over time has been shown to be the best predictor of mortality, however, the minimum 
clinically relevant change needed to predict mortality has varied (Fernández Fabrellas et 
al. 2018). A one-time point measurement of %DLco, however, is considered the main 
predictor of survival (Collard et al. 2003; Fernández Fabrellas et al. 2018; Hamada et al. 
2007). For example, in a study of 78 IPF patients, %DLco, was the only significant predictor 
of 5-year survival (r=0.557, p<0.0001) when controlled for age, sex, and cardiorespiratory 
parameters (Hamada et al. 2007). Review of body mass, body composition and exercise 
capacity as predictors of survival in ILD will be discussed in sections 2.2.1 and 2.2.2.2 of 





2.1.3 Disease Management 
Medical therapeutic options vary among different types of ILD. Early identification, 
aggressive treatment and lung transplantation remain the only recommendations for the 
treatment of ILD (Travis et al. 2013). Treatments may include immunosuppressive therapy 
(Richeldi et al. 2003; Spagnolo et al. 2010), anti-fibrotic or anti-inflammatory agents 
(Hunninghake 2014; Richeldi et al. 2014), and, when medical therapy fails in eligible 
patients, lung transplantation. Regardless of the etiology, the management strategy of ILD 
includes supportive therapy such as home oxygen (Crockett, Cranston, and Antic 2001), 
pulmonary rehabilitation (Holland and Hill 2008; Nakazawa, Cox, and Holland 2017), and 
weight optimization (Alakhras et al. 2007). Guidance related to weight optimization in ILD 
is limited and based on research related to body weight. Weight related research will be 
discussed in the following sections.     
 Nutrition-Related Knowledge to Date 
Little is known about the influence of nutritional status on the clinical course of ILD, a 
potentially important implication on the outcome, functional capacity and quality of life of 
these patients. Existing research is limited by its focus on weight and BMI as measures of 
nutrition status. Therefore, current research does not fully address the influence of body 
composition and overlooks the importance of a comprehensive nutrition assessment.   
2.2.1 Body Mass 
Body mass impacts the ability to breath, and thereby health status in ILD patients. Patients 
with greater weight losses, especially lean body mass, have the greatest deterioration in 
lung function (Tynan and Hasse 2004). Alternatively, obesity complicates breathing and 
results in an increased workload and decreased functional exercise capacity (Tynan and 
Hasse 2004). Therefore, in general, improving any patient’s nutritional status through 
appropriate weight management should lead to an improved quality of life and improved 
disease management.  
Interestingly, multiple studies have found that increased BMI is correlated with an 





al. found that obesity (BMI >30 kg/m2) had a protective effect on morbidity of IPF patients 
as compared to overweight (BMI 25-24.9 kg/m2) and normal weight (BMI <25 kg/m2) 
patients. Mura et al. (2012) reported that for every 1-unit increase in BMI there was an 
11% lower risk of death at 3-year follow-up (HR 0.89, p=0.0155). The concept of obesity 
being protective suggests an inverse epidemiological effect, in that, increased weight may 
offer protection against malnutrition and protect against potential harsh effects of medical 
treatments (Alakhras et al. 2007). In support of this, progressive weight loss (greater than 
5% of total body weight in 1 year) has also been found to be an independent predictor of 
decreased survival in IPF (Nakatsuka et al. 2018). Although literature is largely focused 
within IPF cases, one study, which included a diverse group of ILDs, including connective 
tissues disease-associated ILD, chronic hypersensitivity pneumonitis, and unclassifiable 
subtypes, found that a loss in BMI greater than 5% in 1 year was associated with 
significantly shorter survival times, as well had a 2-fold higher risk of death compared to 
those with a less than or equal to a 5% loss in BMI in 1 year (Pugashetti et al. 2018). 
However, when assessed across ILD subtypes, the association between BMI decline and 
survival was found to be significant in IPF and unclassifiable ILD, but not connective 
tissues disease-associated ILD nor chronic hypersensitivity pneumonitis (Pugashetti et al. 
2018). However, these results may have been limited by small sample size in the 
connective tissues disease-associated ILD and chronic hypersensitivity pneumonitis 
subtypes.  
Collectively, these studies have not fully explored the influence of body mass across many 
ILD subtypes, nor have they addressed the influence of fat-free mass or body fat mass on 
survival. In other disease states, the obesity paradox,  or the hypothesis that increased body 
fat mass is protective only if fat-free mass is adequate, has been validated (Gonzalez et al. 
2014). This suggests that BMI alone does not provide a complete picture of health.  
2.2.2 Body Composition 
Current research has failed to consider the impact of body composition as part of the 
protective effect of increased BMI in ILD patients. A burgeoning area of research involves 
the investigation of sarcopenia. Sarcopenia is a muscle disease defined by low muscle 





2010). Presence of sarcopenia has been found to be associated with increased mortality, 
infection, and hospital length of stay (Kyle et al. 2005). For the purpose of this dissertation, 
sarcopenia and sarcopenic obesity have been identified using sex-specific cut-offs of 
quantity of estimated fat-free mass index (FFMI) and body-fat mass index (BFMI) obtained 
using BIA as outlined by Kyle et al. (2005). These cut-offs have been used by other groups 
to identify sarcopenia and sarcopenic obesity (Gonzalez et al. 2014; Guida et al. 2019). 
FFMI and BFMI are calculated according to the following equations;  
𝐹𝐹𝑀𝐼 =
𝑓𝑎𝑡−𝑓𝑟𝑒𝑒 𝑚𝑎𝑠𝑠 (𝐹𝐹𝑀) (𝑘𝑔)
ℎ𝑒𝑖𝑔ℎ𝑡2 (𝑚2)
  and  𝐵𝐹𝑀𝐼 =
𝑏𝑜𝑑𝑦 𝑓𝑎𝑡 𝑚𝑎𝑠𝑠 (𝐵𝐹𝑀) (𝑘𝑔)
ℎ𝑒𝑖𝑔ℎ𝑡2 (𝑚2)
.  
Low FFMI have been shown to be a predictor of mortality in various disease states such as 
chronic obstructive pulmonary disease (COPD) (Schols et al. 2005) and liver cirrhosis 
(Chang et al. 2019). Age, sex and height are main biological factors affecting fat-free mass, 
but it may also be affected by environmental factors such as physical activity (Kyle et al. 
2003). Nishiyama et al. (2017), were the first to demonstrate that FFMI, determined using 
BIA, was a significant and independent predictor of survival in a cohort of Japanese IPF 
patients. Specifically, a 36% lower risk of death with every 1 unit increase in FFMI (HR 
0.64, 95% CI (0.43–0.94), p=0.02) was observed (Nishiyama et al. 2017). Conversely, 
results from a conference abstract indicated no significant association between FFMI, 
determined using BIA, and all-cause mortality at 1-year in IPF patients (Patel et al. 2018). 
Of note, neither of these studies controlled for age or sex differences in their analyses of 
FFMI. Therefore, one cannot distinguish whether it is disease-related and age-related 
muscle loss that is associated with decreased survival.  
The following subsections review BIA, its theoretical foundation, conditions and 
contradictions for use, limitations, and comparison to alternative body composition 
assessment methods.  
2.2.2.1 Principles of Bioelectrical Impedance Analysis 
BIA leverages the fact that body tissues vary in water and ionic (electrolyte) concentrations 
and thus act as either conductors or insulators to an electrical current travelling through the 





as effective conductors. In other words, these body compartments offer less resistance to 
an electrical current passing through them. Conversely, fat and bone mass are insulators as 
the electrical current experiences more resistance due to the limited amount or lack of water 
or ionic substances in these components. Therefore, body composition can be estimated 
based on the underlying principle that the impedance of a cylindrical conductor with 
uniform cross-sectional area (CSA) relates to its length, and specific resistivity (ρ) applied 
at a fixed frequency, illustrated in Figure 1 (Kushner 1992).  
 
Figure 1 Cylindrical model of the relationship between the impedance of a current to the 
specific resistivity (𝛒), length (L), cross-sectional area (CSA) and volume (V) of a 
conductor.  
We know that anatomically the body is not a single, symmetrical cylinder with uniform 
cross-sectional area (Mulasi et al. 2015). Rather, BIA approximates the body as five 
cylinders; one for each arm, one for each leg and one for the trunk. Therefore, these 
components of the body collectively contribute to the total body impedance.  Additionally, 
the impedance of a conductor is a function of resistance and reactance according to the 
following equation, 𝑖𝑚𝑝𝑒𝑑𝑎𝑛𝑐𝑒2 = 𝑟𝑒𝑠𝑖𝑠𝑡𝑎𝑛𝑐𝑒2 + 𝑟𝑒𝑎𝑐𝑡𝑎𝑛𝑐𝑒2 (Kushner 1992). R is the 






















and tissues (Lukaski, Kyle, and Kondrup 2017). Reactance is related to the electrical charge 
of the current through cells, tissues and non-ionic substances (Lukaski, Kyle, and Kondrup 
2017). It is these raw bioimpedance measures that may be used in regression equations to 
estimate various components of body composition such as muscle mass, body-fat or body 
water. Generally, these equations are both age and sex specific, and are validated against 
other methods of body composition assessment.  
2.2.2.2 BIA Methods and Contraindications  
BIA should be performed in ideal conditions to reduce measurement error. For instance, 
participants should not exercise in the 24 hours prior to the completion of BIA testing. 
Participants should abstain from eating or drinking within 4 hours of the test and should be 
asked to empty their bladders just prior to the test to reduce inaccurate contributions of 
consumed food or fluid in the BIA results (National Health Nutrition and Examination 
Survery (NHANES) 2000). Electrodes through which the battery powered current flows 
are placed on the surfaces of the hand and foot. See Appendix C for BIA testing protocol 
including images on the proper placement of electrodes and body positioning. At the time 
of the test, limb position should be controlled to prevent the limbs and trunk from touching 
one another. Participants should be supine for 5-10 mins to help equalize body water in 
order to account for potential fluid retention (Kyle, Genton, and Pichard 2013). In cases of 
significant edema, results may be confounded. Therefore, clinical judgement may be 
necessary to assess appropriateness of BIA in specific cases. In our cohort of ILD patients, 
we did not note any patients with significant edema in our clinical assessments.   
There are special cases where BIA is contraindicated. BIA is not recommended to be used 
in pregnant or lactating women. BIA should not be completed on individuals with metal 
implants as the presence of metal will interfere with the measurement of Z, R and Xc 
producing inaccurate results. As well, individuals with pacemakers should not undergo 
BIA measurement as the electrical current may interfere with their implanted device 






Measurement instruments have inherent limitations. Although the underlying principles of 
BIA allow for body composition estimation, they also contain some inaccuracies. First, the 
CSA of the body’s limbs and trunk are not of uniform area, nor perfectly symmetrical as 
stated in the underlying principle of BIA. Secondly, it is assumed that current density 
remains uniform across a conductor, however, the body is not homogeneous. Therefore, 
current density will vary even when travelling through muscle, for example, due to 
intramuscular fat. Additionally, body composition data obtained from BIA are predicted 
values or estimations from regression equations developed for specific populations based 
on age, sex and/or disease state. Generally, these regression equations are proprietary to 
the manufacturer of the equipment, which is the case in the BIA device (BodyStat® 
1500MD) used in this research. Therefore, one cannot say with absolute confidence that 
these estimates are accurate in specific age ranges or disease. Regression equations based 
on raw values of resistance and reactance are published for specific disease states, such as 
COPD (de Blasio et al. 2017), however, there have been no regression equations published 
within the ILD or IPF patient population. Although inherent limitations of the BIA 
principles are not able to be controlled for, efforts should be made to minimize limitations 
which can be controlled such as ensuring patients adhere to pre-testing guidelines, accurate 
electrode and body positioning, and when possible patient specific regression equations 
should be used. 
2.2.2.4 Advantages and Comparison to Other Assessment 
Techniques 
Although BIA has notable limitations, it is important to acknowledge that BIA is a portable, 
quick and non-invasive technique. It is a relatively inexpensive tool which can be used in 
clinical practice to obtain a variety of detailed information related to body composition and 
cell health. Other, more precise, measurement techniques such as the use of dual energy 
X-ray absorptiometry scans, magnetic resonance imaging or computed tomography scans 
measure body composition at the organ and tissue level (Prado, Birdsell, and Baracos 
2009). However, major limitations to the use of dual energy X-ray absorptiometry, 





and, most notably, radiation exposure to participants. Therefore, the ability to use the 
techniques in research is generally limited, and when used these scans likely have been 
previously completed for diagnostic or medical monitoring purposes which are typically 
leveraged retrospectively for research purposes.  
2.2.3 Malnutrition 
Malnutrition has been defined as “a state resulting from lack of intake or uptake of nutrition 
that leads to altered body composition (decreased fat-free mass) and body cell mass (total 
cellular components of the body) leading to diminished physical and mental function and 
impaired clinical outcome from disease” (Cederholm et al. 2015). Early identification of 
malnutrition in chronic diseases is important in order to implement appropriate nutrition 
care plans, thereby improving quality of life and tolerance to medical treatments (Charney 
2008). Individuals at risk of malnutrition may be identified using nutrition screening tools 
such as the Mini Nutrition Assessment®. Mini Nutrition Assessment® is a malnutrition 
screening tool validated for older adults defined by age >65 years (See Appendix D) 
(Bauer et al. 2008).  Once identified as being at risk of malnutrition, individuals should 
undergo in-depth nutrition assessment in order to identify nutritional deficiencies and 
determine degree of malnutrition. The gold standard of nutrition assessment is the 
subjective global assessment (SGA) developed by Detsky et al. 1987 (See Appendix B for 
SGA scoring sheet) (Keith 2008). SGA combines dietary, weight, functional, 
gastrointestinal and disease history with a physical examination to arrive at a categorical 
ranking. SGA will be reviewed in further detail in Chapter 3 including its components and 
various versions developed for specific patient populations.  
To date, only a few nutrition screening tools, such as the Mini Nutrition Assessment® have 
been used to assess risk of malnutrition in ILD/IPF patients, but no studies have used in-
depth nutrition assessments in ILD/IPF. An American study evaluated the nutrition status 
of IPF patients using the Mini Nutrition Assessment®. Results from this study revealed 
that approximately one quarter of participants were at risk of malnutrition while the 
remaining were identified as normal nutritional status (Autore et al. 2013). Although, IPF 
prevalence increases with age, authors concluded that the application of the Mini Nutrition 





Additionally, malnutrition prevalence in ILD has been estimated using single 
anthropometric measures and varies greatly. For instance, a study of 81 IPF patients, of 
which 88% were male, found that 28% of patients were malnourished using fat-free mass, 
4% were malnourished using BMI, and 5% were malnourished using mid-arm 
circumference (Jouneau et al. 2019). In ILD, the prevalence of malnutrition using 
standardized and validated nutrition assessment tools is not well established.  
2.2.3.1 Measurements of Nutritional Indicators 
Trained clinicians, such as registered dietitians (RDs), needed to perform the SGA may 
not be readily available as part of standard care, therefore surrogate markers of nutrition, 
such as raw measures of BIA including PhA and impedance ratio (IR), have been 
suggested in a number of different disease states (Kuchnia et al. 2017; Kyle et al. 2012; 
Kyle, Genton, and Pichard 2013; Malecka-Massalska et al. 2016; Ott et al. 1995; Plank 
and Li 2013). PhA will be discussed in further detail in Chapter 2. 
IR and nutrition status are theorized to relate to each other through their common 
association with alterations in body composition and body cell mass. IR is the ratio of 
impedances at 200kHz and 5kHz obtained using BIA. As described in section 2.2.2.1.1., 
impedance includes two components; the resistance and reactance of a current as it passes 
through the body. This research used multi-frequency BIA. multi-frequency BIA provides 
the advantage of differentiating body water components; intracellular water and 
extracellular water. Total body water is estimated when impedance is measured at high 
frequencies (200kHz) which can pass through cell walls. However, impedance at low 
frequencies (5kHz) have limited capacity to penetrate cell walls, therefore only 







(Rinninella et al. 2018). In healthy individuals, there is a large variation in impedances at 
200kHz and 5kHz resulting in a lower value of IR. However, in malnutrition and disease, 
cell walls can become damaged or weakened, allowing intracellular water to leak into the 
extracellular space which may result in edema or third-spacing (Rinninella et al. 2018).  
Therefore, the impedance at 5hHz, representing extracellular water, will approach that of 





poorer cellular health, abnormal hydration status and malnutrition (Kuchnia et al. 2017; 
Lukaski, Kyle, and Kondrup 2017; Rinninella et al. 2018).  
Although there has been growing interest in the use of raw bioimpedance parameters as 
prognostic indicators and surrogate markers of nutrition status, no studies to date have 
explored the relationship between PhA nor IR in ILD. As well, limited research exists on 
the relationship between IR and nutrition status. Using total body protein as a measure of 
nutrition status, Plank and Li (2013), demonstrated that a high IR, defined as >0.78 in males 
and >0.82 in females, established from healthy volunteers, had significantly greater odds 
of malnutrition [OR 4.15, CI 95% (1.77-9.75), p=0.001]. However, no studies have 
compared IR with nutrition status assessed using nutrition screening tools, nor 
comprehensive nutrition assessment methods such as SGA. Furthermore, the overall body 
of research on IR and nutrition is lacking in its validation in clinical settings. Although IR 
cut-offs have been suggested in other populations such as hospitalized inpatients (Plank 
and Li 2013), in order to determine appropriate IR cut-off points population reference 
norms are required. Recently, an American study using the National Health and Nutrition 
Examination Survey 1999–2004 database published population reference values of PhA 
and IR, therefore establishing cut-off points in a diverse American sample (Kuchnia et al. 
2017). Further studies are needed to continue to validate IR as an accurate and appropriate 
marker of nutrition status in health and disease.  
2.2.4 Drugs and Nutrition  
There is no cure for ILD aside from lung transplantation. Medical therapies are not curative, 
rather they act to slow or stop disease progression (Trawinska, Rupesinghe, and Hart 2016). 
In general, ILD/IPF medical therapies are used for either their anti-fibrotic, anti-
inflammatory or immune suppressing effects. However, these medications come with risks 
of adverse events. Adverse events are the most common reason for patients to discontinue 
medications (Trawinska, Rupesinghe, and Hart 2016). In general, medication-related 
gastrointestinal (GI) adverse events can be managed through dose adjustment, treatment 
interruption, and/or symptoms management (Quinn, Wisse, and Manns 2019). Therefore, 





patients in order to manage these medication-related adverse events is an important 
component of ILD/IPF management.  
2.2.4.1 Corticosteroids 
Corticosteroids have anti-inflammatory properties which in early ILD management were 
thought to be able to slow or stop the progression of fibrosis, respiratory failure and death 
(Kim and Meyer 2008). Over the years, corticosteroids have not shown to be the most 
effective therapy they were once expected to be. Therefore, previous clinical guidelines 
have suggested, based on very-low quality evidence, that only a minority of patients with 
acute exacerbations of their disease will experience a treatment benefit with corticosteroids 
(Kim and Meyer 2008; Raghu et al. 2011). Nevertheless, corticosteroids, such as 
prednisone, may be used in clinical practice. Common nutrition-related side effects, 
depending on the dosage, include weight gain related to increased appetite or fluid retention 
(US FDA approved prescribing information 1955). Several other ILD medications have 
shown to be effective in the management of ILD which are discussed in the following 
subsections.  
2.2.4.2 Pirfenidone (Esbriet®) 
Pirfenidone is an anti-fibrotic medication used in IPF patients and acts to suppress the 
activity of fibrosis-associated pathways (Oku et al. 2008; Trawinska, Rupesinghe, and Hart 
2016). Pirfenidone is also used for its antioxidant and anti-inflammatory effects (Somogyi 
et al. 2019). A serious side-effect of pirfenidone includes photosensitivity. Patients are 
instructed to limit their sun exposure and to use sun protective clothing and sun blocks 
while on this medication (Kreuter 2014). Therefore, patients on pirfenidone have limited 
vitamin D synthesis through the skin and must rely solely on diet and supplementation to 
meet their vitamin D needs. Research has shown that ILD patients have a high incidence 
of vitamin D deficiency (Hagaman et al. 2011), osteopenia and osteoporosis (Alhamad and 
Nadama 2015). Other observed side effects with pirfenidone use are nausea, diarrhea, 
vomiting, anorexia and dyspepsia/gastroesophageal reflux disease (Galli et al. 2017). In 





gastroesophageal reflux disease which occurred in 36% and 18.5% of cases, respectively 
(Galli et al. 2017).  
2.2.4.3 Nintedanib (OFEV®) 
Nintedanib is an anti-fibrotic medication used in IPF to slow the rate of lung function 
decline (Galli et al. 2017; Trawinska, Rupesinghe, and Hart 2016). The most common GI 
side effect experienced by patients is diarrhea. In clinical trials, 62% of patients 
experienced diarrhea, 24.5% experienced nausea, 12% experienced vomiting and 11% 
experienced anorexia (Galli et al. 2017). Additionally, over half of the adverse events 
resulting in drug discontinuation were related to GI-associated adverse events (Galli et al. 
2017).  
2.2.4.4 N-acetylcysteine (NAC) 
N-acetylcysteine (NAC) is an oral or inhaled antioxidant used in the treatment of IPF to 
help prevent damage to the lungs (Trawinska, Rupesinghe, and Hart 2016). Common 
adverse reactions can include nausea and vomiting, however, a double-blind, placebo-
controlled trial showed no significant difference in adverse events in NAC versus placebo 
(Martinez et al. 2014). Although it has been proven to be safe and well tolerated (Martinez 
et al. 2014), current clinical practice guidelines, however, have stipulated a conditional 
recommendation against its use due to non-significant changes in lung function nor 
survival rates associated with its use (Raghu et al. 2015).   
2.2.4.5 Mycophenolate Mofetil (CellCept®, Myfortic®)  
Mycophenolate Mofetil (MMF) is a potent immunosuppressive and anti-inflammatory 
medication typically used to prevent rejection after organ transplant. However, research 
has suggested that MMF may also have an anti-fibrotic effect. Therefore, its use in certain 
ILDs including connective tissues disease-associated ILD and chronic hypersensitivity 
pneumonitis has grown. However, in IPF, only small, low-powered studies have been 
published and provide mixed results (Nambiar, Anzueto, and Peters 2017). The most 
common GI-associated adverse events include constipation, nausea, diarrhea, vomiting, 





patients have noted diarrhea to be the most frequent GI-associated symptom (Omair, 
Alahmadi, and Johnson 2015). Despite its proposed anti-fibrotic effects, current clinical 
practice guideline do not include recommendations for its use in IPF patients (Raghu et al. 
2015). 
2.2.4.6 Antacids  
Antacids, such as, protein pump inhibitors for management of gastroesophageal reflux 
disease are commonly prescribed in ILD patients to manage adverse effects resulting from 
ILD/IPF medications. As well, there is a high incidence of gastroesophageal reflux disease 
in IPF (Trawinska, Rupesinghe, and Hart 2016). This has led some to believe that 
gastroesophageal reflux disease plays a role in the development and progression of IPF, or 
many be an underlying cause of chronic cough in IPF (Raghu et al. 2006; Trawinska, 
Rupesinghe, and Hart 2016).  
It has been reported that prevalence of ILD increases with age (Olson et al. 2018).  
Nutritional deficiencies associated with aging, confounded by nutrient-drug interactions 
common in the ILD population puts ILD/IPF patients at higher risks of deficiencies. For 
example, absorption of vitamin B12 first requires enough acid content in the stomach to be 
able to release vitamin B12 from the protein it is attached to in food. However, with age 
stomach acidity tends to decrease, and confounding this, protein pump inhibitors act to 
reduce gastric acid secretion (McCaddon 2013). Therefore, especially in older patients with 
IPF/ILD on protein pump inhibitors, absorptive capacity of vitamin B12 can be reduced 
affecting patients’ serum blood levels leading to deficiency.  
In summary, from a nutrition perspective, use of ILD medications puts patients at risk of 
malnutrition whether it be through poor intake, decreased appetite, malabsorption, or any 
combination of these. Therefore, specific and therapeutic nutritional support to manage 
medication adverse events can help to prevent and/or correct malnutrition in ILD patients. 
Therefore, it is important to be familiar with these medications and aware of their side 





 Exercise Capacity and Nutrition 
Diminished exercise capacity is common among individuals with ILD (Mendes et al. 
2015), which negatively contributes to their ability to participate in normal activities of 
daily living, and thus compromises quality of life (Hansen and Wasserman 1996; Mendes 
et al. 2015). Exercise capacity is measured using the six-minute walk test which is a routine 
component in the standard care of ILD monitoring and management. The six-minute walk 
test is a reliable and validated tool in ILD patients (Du Bois et al. 2011; Eaton et al. 2005; 
Lederer et al. 2006; Serajeddini, Rogliani, and Mura 2018) which involves participants 
walking as far and fast as they are able for 6 minutes. A change of 30 meters is generally 
considered a clinically significant change in 6MWD in IPF patients (Fernández Fabrellas 
et al. 2018; Nathan et al. 2015). Interestingly, six-minute walk test guidelines (American 
Thoracic Society (ATS) 2002) suggest poor nutrition as a potential underlying cause of 
low 6MWD and indicate that it should be further investigated.  
Diminished exercise capacity in ILD is multifaceted with pathophysiological factors such 
as impaired of gas exchange, altered respiratory mechanics, limited pulmonary circulation 
and peripheral muscle dysfunction (Holland et al. 2008; Raghu et al. 2011). In other chronic 
lung diseases, such as COPD, low 6MWD was associated with significantly greater odds 
of poor nutrition status assessed using the Mini Nutrition Assessment® [OR 0.835 95% CI 
(0.735-0.908), p=0.005] (Matkovic et al. 2017). Similarly, worsened nutrition status 
assessed using Mini Nutrition Assessment® was associated with worse dyspnea score [OR 
22.888, 95% CI (2.103-249.065), p=0.01], and lung function (FEV1/FVC ratio) [OR 0.898, 
95% CI (0.826-0.977), p=0.012] in COPD patients (Mete et al. 2018).   
In ILD, nutrition support is noted as a non-exercise component in pulmonary rehabilitation 
programs (Nakazawa, Cox, and Holland 2017). However, specific nutrition 
recommendations are not included in best practice guidelines (Raghu et al. 2015; Travis et 
al. 2013). No studies have explored the influence of poor nutrition status on diminished 
exercise capacity in ILD, therefore, research in this area is needed to better understand the 






There are notable nutrition-related concerns associated with ILD and its management. 
These concerns include maintaining a healthy body weight, optimizing body composition 
and managing medication side-effects. In addition, poor nutrition status may be negatively 
impact ILD patients’ functional level of exercise of everyday physical activities and thus 
quality of life. Identifying and correcting malnutrition requires specialized skills and 
assessment tools. Unfortunately, nutrition professions such as RDs needed to complete 
these assessments may not be part of the health care team in standard ILD care. Therefore, 
nutrition concerns in ILD patients may not be identified, nor appropriately managed. The 
following chapter reviews the appropriateness and accuracy of PhA as an objective, 





Chapter 3  
3 Literature Review – Part II 
Is Phase Angle an Appropriate Indicator of Malnutrition 
in Different Disease States? A Systematic Review 
Publication citation: Rinaldi S, Gilliland J, O’Connor C, Chesworth B, Madill J. 2018. 
“Is phase angle an appropriate indicator of malnutrition in different disease states? A 
systematic review.” Clinical Nutrition European Society for Parenteral and Enteral 
Nutrition 29: 1-14. doi:https://doi.org/10.1016/j.clnesp.2018.10.010. 
 Abstract 
Background & aims: The subjective global assessment (SGA) classifies malnutrition 
severity via a simple bedside assessment. Phase angle (PhA) is an indicator of cell 
integrity and has been suggested to be indicator of nutritional status.  
Objective: To explore the relationship between PhA and SGA.  
Methods: Relevant studies published through October 31, 2017 were identified using 7 
electronic databases. Articles were included for review if they included comparison data 
between SGA and PhA within adult disease populations. Evidence quality was assessed 
using the Grading of Recommendations, Assessment, Development and Evaluation 
(GRADE) guidelines and methodological quality was assessed using the Quality 
Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool.   
Results: 33 articles within four disease states (liver, hospitalization, oncology and renal) 
met inclusion criteria for review. Results were limited by restricting the database search 
to articles published in English only, and by the inherent difficulty of comparing 2 
methods which are both influenced by the operator.  
Conclusion: Based on GRADE guidelines, evidence quality received a grade of Low. 
Based on QUADAS-2, 61% of studies had high risk of bias in the index test (PhA), while 
all other domains had low risk. It is not possible to conclude that PhA is an accurate 






Malnutrition is a common concern in both chronic and acute disease with significant 
implications on survival, quality of life, medical complications, and other socioeconomic 
issues (McWhirter and Pennington 1994; K. Norman, Pichard, et al. 2008; Pirlich et al. 
2005). There is a broad range of methods for nutrition assessment available to clinicians 
(White et al. 2013). Subjective Global Assessment (SGA) is a nutritional assessment 
method which classifies malnutrition severity via a bedside assessment (Detsky et al. 
1987). It is the gold standard method to identify malnutrition (Keith 2008), and has been 
validated in many disease states and clinical settings (Baccaro et al. 2007; Baker et al. 
1982; Cooper et al. 2002; Correia and Waitzberg 2003; Jerin et al. 2003; Kondrup et al. 
2003; Pirlich et al. 2005). SGA combines dietary, weight, functional, gastrointestinal and 
disease history with a physical examination to arrive at a category ranking. SGA-A 
represents a well-nourished state, SGA-B represents moderate malnutrition or suspected 
of being malnourished and SGA-C represents severe malnutrition (Detsky et al. 1987). 
Since its initial development, SGA has been adapted by various groups. Hasse et al., 1993 
developed an adapted-SGA for liver disease, which accounts for additional clinical 
conditions such as encephalopathy, infection, kidney function, and varices (Hasse et al. 
1993).  The CANADA-USA Peritoneal Dialysis Study Group developed a 7-point 
modified SGA (7p-SGA) (Churchill, Taylor, and Keshaviah 1996). Kalantar-Zadeh and 
colleagues, proposed a quantitative scoring system known as the quantitative-SGA 
(QSGA), also referred to as Dialysis Malnutrition Score (Kalantar-Zadeh et al. 1999). 
The Patient-Generated SGA (PG-SGA) combines a patient-generated component with a 
professional assessment and is used most commonly in oncology and chronic catabolic 
conditions (Bauer, Capra, and Ferguson 2002; Ottery 1996; Ottery and Jager-Wittenaar 
2014).  
Whereas SGA evaluates nutritional status subjectively, phase angle (PhA) is strictly an 
objective measure. Unlike SGA which requires a comprehensive assessment by a trained 
evaluator, PhA measurement is a simple, quick and non-invasive technique. PhA is a 
measure of the resistance and reactance of a current as it passes through tissues of the 





Resistance is affected by the amount of fluid in the tissues of the body, whereas reactance 
is affected by the type of body cells and their related permeability (Norman et al. 2015). 
Age, sex, and BMI are the main biological factors affecting PhA (Norman et al. 2012). 
PhA may also be affected by level of physical activity, fluid status, and body composition 
(Norman et al. 2012; Tynan and Hasse 2004). The calculation of a standardized phase 
angle (SPhA) aims to account for these confounding factors. A SPhA is calculated as a z-
score which may be based on established population reference values stratified by a 
combination of age, sex, BMI, or ethnicity (Barbosa-Silva et al. 2005; Barbosa-Silva, 
Barros, and Larsson 2008; Bosy-Westphal et al. 2006; Kyle et al. 2001; Kyle et al. 2004).  
PhA has been suggested to be a prognostic, health, functional and nutrition indicator (Ott 
et al. 1995; Schwenk et al. 2000; Selberg and Selberg 2002). Generally, a low PhA 
indicates cell membrane breakdown and thus an altered ability to store energy and 
complete metabolic functions (Norman et al. 2012). Conversely, a high PhA indicates 
intact cell membranes and high body cell mass (Norman et al. 2012). Thus, as PhA 
reflects the quantity and types of tissues, such as muscle and fat mass, including 
hydration status, it is hypothesized that PhA could reflect nutritional status. It is thought 
that metabolic changes, such as those in cell membranes, are first affected by 
malnutrition (Barbosa-Silva 2008). Thus, PhA may be able to detect malnutrition at an 
early stage and may be useful in evaluating the effectiveness of nutrition therapy, before 
improvements in nutritional status can be detected by other assessment methods such as 
SGA. To this end, many studies have used PhA cut-off points to identify malnutrition 
(Antunes et al. 2012; Selberg and Selberg 2002). Many of these PhA cut-off points were 
derived using survival as its reference standard (Barbosa-Silva and Barros 2005; 
Fernandes et al. 2012; Mattar 1995; Máttar 1996; Paiva et al. 2010). Thus, the reliability 
of these cut-offs to identify malnutrition is unknown.  
Therefore, the aim of this study is to evaluate the relationship between bioelectrical phase 
angle and malnutrition severity as measured by the Subjective Global Assessment in 
acute or chronically ill adults ≥18 years through a systematic review of cross-sectional 






The systematic review protocol was registered on PROSPERO (no. CRD42016050876). 
The current systematic review followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines. Studies were selected using the following 
inclusion criteria: 1) original research published in English, 2) assessment of malnutrition 
using SGA and its adapted versions, with comparison to PhA or SPhA, and 3) individuals 
>18 years with acute or chronic disease/illness. 
3.3.1 Data Sources 
Relevant studies were identified by searching 7 electronic bibliographic databases: 
Scopus, CINAHL, PubMed, ProQuest Nursing and Allied Health, Medline, Cochrane, 
and ProQuest Dissertation and Thesis. Search terms used were ‘phase angle’ AND 
(‘subjective global assessment’ OR SGA), including their MeSH terms. The search was 
limited to human studies published in English through October 31, 2017. Reference lists 
of all relevant studies, and relevant reviews were examined for other relevant studies, 
although none were identified. Two investigators independently reviewed titles and 
abstracts to select potentially eligible articles for document screening. If discordance 






Figure 2 Flowchart of selecting studies for the systematic review 
3.3.2 Data Extraction and Synthesis  
One reviewer independently extracted study information and then verified by a second 
reviewer. Data was organized in an excel spreadsheet which included authors, year of 
publication, country of origin, study objective, study population (clinical setting, sample 
size, sex and age), subjective method(s) of nutritional assessment, BIA model used, PhA 
cut-off, analyses between PhA and SGA and limitations of the study.  A meta-analysis 
was not performed as a variety of previously derived cut-off values were used which did 
not allow for agreement statistics. Data were synthesized by disease group to allow for 
more direct comparison between study results. Within each disease group, differences in 
findings were compared and reasons for these differences such as heterogeneity, study 






3.3.3 Data Evaluation and Quality Assessment 
The articles were evaluated by two reviewers using two quality assessment tools: the 
Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
guidelines (Guyatt et al. 2011) and the Quality Assessment of Diagnostic Accuracy 
Studies (QUADAS-2) tool (Whiting et al. 2011). The GRADE approach provides a 
quality rating of scientific evidence ranging from Very Low to High. This approach is 
widely used in systematic reviews and meta-analyses in the development of clinical 
practice guidelines and health care recommendations (Guyatt et al. 2011). Although the 
GRADE approach is a highly regarded tool, a second quality assessment tool designed 
specific for diagnostic accuracy was also used to assess methodological quality. The 
QUADAS-2 tool is recommended for use in systematic reviews involving diagnostic 
accuracy studies. QUADAS-2 evaluates the risk of bias and applicability within four 
domains observed in diagnostic accuracy studies: patient selection, index test, reference 
standard and flow and timing. QUADAS-2 does not generate a quality score, instead it 
allows the user to summarize the number of studies found at low, high or unclear risk of 
bias and applicability across domains. To indicate an overall utility of PhA or SPhA as a 
nutritional indictor in disease, quality assessment using the GRADE approach and the 
QUADAS-2 tool was completed within each disease group separately and across all 
studies. Both researchers involved in data extraction (SR and JM) were trained in the use 
of GRADE guidelines and the QUADA-2 tool.  
For the purposes of data extraction, articles with reported ĸ coefficients (kappa) were 
interpreted as previously recommended by Altman (1991): ĸ < 0.20 (poor agreement); 
0.21 ≤ ĸ ≤ 0.40 (fair agreement); 0.41 ≤ ĸ ≤ 0.60 (moderate agreement); 0.61 ≤ ĸ ≤ 0.80 
(good agreement); ĸ > 0.80 (very good agreement) (Altman 1991).  
 Results 
Database searches resulted in 298 articles. All articles were exported into a reference 
management system and merged to remove duplicates, with 153 articles retained for 





years ranged from 1993 to 2017. Study characteristics are displayed in Table 1. Study 





Table 1 Study characteristics of the literature on the comparison between PhA and SGA in malnutrition assessment 
Author, Year County 
Participant 
characteristics 
Sample size  
(% male) 
Age (years) 




(Wagner et al. 
2011) 
Austria 
Years after Tx:  
Group A: <5  
Group B: 5-10  
Group C: >10  
Group A: n=11 
Group B: n=19  
Group C: n= 41  
Sex not specified 
Group A: 58 ± 8 
Group B: 59 ± 6 
Group C: 58 ± 10 
RJL-101 
(Bakshi and Singh 
2016) 
India 
End-stage liver disease 
patients admitted to 
hospital for liver Tx 
n=54  
(n=20 underwent BIA)  
Sex not specified 
48.3 ± 10.2 
MC-180MA 
(Tanita) 
(Peres et al. 2012) Brazil CLD n=66 (57.6%M) 59 (41-79) RJL-101 
(Liboredo et al. 
2015) 









n=279 (31%M) 50.4 years 
RJL Quantum 
101 







F: 51.0  
Biodynamics 
model 310 

















n=98 (32.7%M) 46.3 ± 13.6 
Biodynamics 
model 310e 








M: 39.8 ± 12.7  
F: 38.6 ± 14.1  
Controls:  
M: 39.7 ± 12.6  
F: 38.4 ± 13.6  
RJL-101 











M: 49.8 ± 19.7  
F: 56.4 ± 23.2  
Controls: 
M: 49.6 ± 19.6  
F: 56.2 ± 22.9  
RJL-101 
(Guerra et al. 
2015) 
Portugal 
Long and short LOS 
hospitalized patients 
Short LOS:  
n=311 (45.2%M);  
Long LOS: 
 n=371 (54.8%M) 
Short LOS:  
55 (IQR 24) 
Long LOS: 











n=242 (50%M)           
SGA-A: 60.3  
(IQR 42.1-68.3)               
SGA-B: 57.1  
(IQR 33.5-66.4)            













endocrinology and GI 
patients 




(Gupta et al. 2004) USA 
Stage IV pancreatic 
cancer 
n=58 (60.3%M)  
*SGA completed in 
n=51         
At diagnosis:  
56.2 ± 1.5  
RJL-101Q 
(Gupta et al. 2008) USA Advanced CRC n=73 (50.6%M)                
At diagnosis:  
56 ± 11.4  
RJL-101Q 
(Abe Vicente et al. 
2013) 
Brazil 
Group 1: Active gastric 
or CRC 
Group 2: treatment 
follow-up patients, 
tumor free >3 months 
Group 1:  
n=75 (48%M) 
Group 2:  
n=62 (45.2%M)                          
Group 1:  
60.2 ± 12.2  
Group 2:  
61.3 ± 11.6  
Biodynamics 
450 
(Maurício et al. 
2013) 
Brazil CRC n=70 (44.3%M)                
M: 60.1 ± 14.0  
F: 60.7 ± 14.8 
RJL Quantum 
X 






n=43 (60.5%M); Not reported Not reported 
(Malecka-
Massalska et al. 
2016) 
Poland Newly diagnosed HNC n=75 (89.3%M)              
At diagnosis:  












n=75 (89.3%M) 56.88 ± 8.21 
SFB7 BioImp 
v1.55 
(Mulasi et al. 
2016) 
USA 
HNC patients after 3 
months of chemo-
radiotherapy 
n=19 (94.7%M)              59 ± 7 
QuadScan 
4000 





n=203 (48.3%M)              Mean: 63.4  
Nutriguard M 
(Data Input) 
(Norman et al. 
2010) 
Germany 
Solid or hematologic 
tumor disease 
















with Stage II-CKD  
n=75;  
Sex not specified. 
64.8 ± 11.6  
Biodynamics 
450 
(Passadakis et al. 
1999) 
India CAPD n=47 (55.3%M) 
M: 58.9 ± 14.6 
F: 56.2 ± 18.3  
Not reported 
(Gu et al. 2008) China CAPD n=124 (41.1%M) 59.9 ± 12.8 
Hydra analyzer 
(Xitron Tech) 
(Enia et al. 1993) 
Italy 
 
HD and CAPD 
n=59 (64.4%M);               
n=36 HD, n=23 CAPD                       





(Santin et al. 2018) Brazil HD n=104 (70.2%M) 70.9 ± 6.9  
Biodynamics 
450 








61.6 ± 14.5  
Controls:  




(Rimsevicius et al. 
2016) 
Lithuania HD n=99 (58.7%M) 58.7 ± 14.38  
Biospace 
InBody S10 
(Vannini et al. 
2009) 
Brazil HD n=52 (67.3%M) 55 ± 13.6  
Biodynamics 
450 
(de Oliveira et al. 
2010) 
Brazil HD n=58 (47.3%M) 49.22 ± 14.85 Not specified 
CAPD: continuous ambulatory peritoneal dialysis; CKD: chronic kidney disease; CLD: chronic liver disease; CRC: colorectal 


















malnutrition:    
Group A: 18.2% (SGA), 
81.2% (PhA) 
Group B: 10.5% (SGA), 
31.6% (PhA)  
Group C: 4.8% (SGA), 
31.7% (PhA) 
- 













75% (PhA), 88.9% (SGA-
B+C) 
ĸ=0.44 (90% agreement) 
Sensitivity: 94.4%; 
Specificity: 50% 
Moderate agreement between 
PhA and SGA 
 








5.18° (range: 1.86°-8.40°) 
SGA-A:  
5.31° (range: 3.45°-7.42°) 
SGA-B+C:  
4.35° (range: 1.86°-6.73°), 
p=0.005 
- 
No significant difference 
between sexes (p=0.59). 













50% (PhA), 66.7% (SGA). 
Total:  
5.3° (range: 2.2°-6.9°);   
SGA-A:  
6.0° (range: 4.2°-6.9°);   
SGA-B+C:  
4.8° (range: 2.2°-6.1°), NS 
- 
Median PhA was not 
significantly correlated with any 
clinical parameter. 
No significant difference in PhA 
between SGA groups. 
Hospitalized Patients 
(Barbosa-




SGA-A: 6.65° [95% CI 
(6.33°-6.98°)] 
SGA-B: 6.13° [95% CI 
(5.75°-6.50°)] 
SGA-C: 4.70° [95% CI 
(4.03°-5.36°)], p<0.001   
Female:  
SGA-A: 6.36° [95% CI 
(6.23°-6.50°)] 
SGA-B: 5.14° [95% CI 
(4.82°-5.46°)] 
SGA-C: 4.22° [95% CI 
(3.02°-5.43°)], p<0.001   
 
ĸ=0.39 [95% CI (0.26-
0.51)]  
Male: ĸ=0.27 [95% CI 
(0.07-0.47)] 
Sensitivity: 31%; 
Specificity: 97%  
Female: ĸ=0.46 [95% CI 
(0.31-0.61)] 
Sensitivity: 47%; 
Specificity: 94%  
 
PhA significantly decreased with 
worsening level of malnutrition 
for the total sample and within 
each sex group.   
Fair agreement between SGA 
and PhA in all participants and 
males, and moderate agreement 
in females.   
Optimal PhA cut-off could not 
be obtained. Cut-off with best 
balance of sensitivity and 
specificity was 6.3° (AUC: 0.72) 








SGA <-1.65 SD 
Prevalence of malnutrition: 




ĸ=0.038 [95% CI  
(-0.068-0.144)] 
Male:  
ĸ=0.041 [95% CI  
(-0.135-0.216)] 
Female:  
ĸ=0.029 [95% CI  
(-0.092-0.150)] 
SPhA was significantly reduced 
in malnourished versus well-
nourished patients. 
Moderate agreement between 
PhA and SGA in males, and fair 
in all participants and females. 
(Cardinal et 
al. 2010) 
SGA  <-0.8 SD 
Total: 
SGA-A: 0.3 ± 0.1 SD;  
SGA-B+C: -0.8 ± 0.2 SD, 
p<0.001 
Male:  
SGA-A:  0.3 ± 0.2 SD;  
SGA-B+C: -0.7 ± 0.3 SD, 
p=0.001 
Female:  
SGA-A: 0.3 ± 0.1 SD;  
SGA-B+C: -1.0 ± 0.5 SD, 
p=0.018 
ĸ=0.45 [95% CI (0.25 to 
0.65)] 
SPhA was significantly reduced 
in malnourished versus well-
nourished patients in the total 
group and in each sex group. 
Moderate agreement between 








n et al. 2011) 
SGA <-0.8 SD 
Total:  
   SGA-A: 0.0 SD [95% CI 
(-0.2-0.3)]  
   SGA-B+C: -0.7 SD [95% 
CI (-1.2-0.2)],    p=0.001   
Male:  
   SGA-A: 0.1 SD [95% CI 
(-0.4-0.6)]  
   SGA-B+C: -1.2 [95% CI 
(-1.8-0.6)], p=0.002   
Female:  
   SGA-A: 0.0 [95% CI (-
0.3-0.3)]  
   SGA-B+C: -0.5 [95% (CI 
-1.9-0.1)], NS  
Total: ĸ=0.27 [95% CI 
(0.06-0.48)] 
Sensitivity: 82.6%  
Specificity: 40.6%  
Male:  
ĸ=0.39 [95% CI (0.04-
0.73)] 
Female:  
ĸ=0.21 [95% CI (-0.04-
0.47)] 
Significant difference in SPhA 
between malnourished and well-
nourished groups in all patients 
and male patients, but not in 
female patients. 
Optimal SPhA cut-off obtained 
was -0.63 SD with 72.4% 
sensitivity and 68.1% specificity. 






  Male: 6.6° ± 1.1° 
  Female: 5.8° ± 0.96°, 
p<0.001  
Controls:  
  Male: 7.55° ± 0.95° 
  Female: 6.5 ± 0.08°, 














PhA was significantly greater in 
controls versus patients for both 
sexes. 
Moderate agreement between 
PhA and SGA in males and 
females. 
Optimal PhA cut-offs were 
determined to be <4.6° for 












<5.0° M  
(Kyle et al. 
2012) 
Patients:  
  Male: 6.0° ± 1.4° 
  Female: 5.0° ± 1.3°, 
p<0.05 
Controls:  
  Male: 7.1° ± 1.2° 
  Female: 6.0 ± 1.2°, 
p<0.05  
SGA-A: RR 1.4 [95% CI 
(1.0-2.1)], p=0.046  
SGA-B: RR 3.8 [95% CI 
(2.9-4.9)], p<0.001 
SGA-C: RR 7.2 [95% CI 
(5.7-9.0)], p<0.001 
- 
PhA was significantly greater in 
controls versus patients for both 
sexes. 
Patients with moderate 
malnutrition were 3.8 times 
more likely to have a low PhA 
than healthy subjects. 
Patients classified with severe 
malnutrition were 7.2 times 
more likely to have a low PhA 





<5.0° M  




Short LOS, Long LOS 
6.5%, 16.7% (PhA) 
30%, 14% (SGA-B) 
30%, 13% (SGA-C) 
ĸ=0.17  
(60.5% agreement) 
Poor agreement between PhA 





SGA  N/A 
SGA-A:  
5.39° (IQR 4.72°-6.05°)  
SGA-B:  
5.02° (IQR 4.42°-5.65°) 
SGA-C:  
4.17° (IQR 3.50°-5.20°) 
   SGA-A vs SGA-B, 
- 
PhA significantly decreased with 






   SGA-B vs SGA-C, 
p<0.0001 







Total: 4.91° ± 1.17°  
(range, 1.62° - 8.51°; -7.2 - 
2.5 SD)   
PhA Linear regression: 
SGA-B: ß=-0.538  
(12.6% estimate of effect) 
p<0.0001 
SGA-C: ß =-0.935  
(26.5% estimate of effect) 
p<0.0001 
SPhA Linear regression: 
SGA-B: ß=-0.743  
(27.2% estimate of effect) 
p<0.0001 
SGA-C: ß=-1.307  
(58.2% estimate of effect) 
p<0.0001 
- 
PhA was significantly greater in 
males. PhA and SPhA were 
significantly lower in 
malnourished versus well-
nourished patients. 
Moderate and severe 
malnutrition were significant 
















No significant correlation 
between PhA and SGA. 






Median PhA:  
SGA-A: 6.12°  
SGA-B+C: 5.18°, p=0.005      
Correlation: ρ=0.33, 
p=0.004 
AUC=0.7 [95% CI (0.57-
0.820)], p=0.005 
ROC curves: 
PhA  Sens Spec 
<5.2° 51.7% 79.5% 
<5.3° 55.7% 68.2% 
<5.5° 58.6% 65.9% 
<5.7° 69.0% 56.8% 
<6.0° 82.8% 54.5% 
 
PhA was significantly reduced in 
malnourished versus well-
nourished patients. 
Fair agreement between PhA and 
SGA. 
PhA cut-off 5.9° in males with 
progressive disease had the best 
balance of sensitivity (100%) 












Prevalence of malnutrition:  
Group 1: 
66.6% (PG-SGA); 36% 
(PhA) 
Group 2:  
30.9% (PG-SGA); 14.5% 
(PhA) 
Group 1:  
Sensitivity: 44%; 
Specificity: 80% 
Group 2:  
Sensitivity: 38.4%; 
Specificity: 91.2% 
Significant association between 
PhA and PG-SGA in Group 1 







SGA-A: 5.5° ± 0.6° 
SGA-B: 5.4° ± 1.0° 
SGA-C: 4.9° ± 1.1°, 
*p<0.05 between SGA-A 
and SGA-C 
ĸ=0.11, p<0.05 
PhA was significantly reduced in 
severely malnourished versus 
well-nourished patients only. 













SGA-A: 6.7° (5.6-7.4)° 
SGA-B: 5.1° (3.8-6.0)° 
SGA-C: 4.5° (2.6-6.4)° 
   SGA-A: vs SGA-C, 
p<0.05 
   SGA-A vs SGA-B, p<0.05 
   SGA-B vs SGA-C, NS 
ĸ<0.20 
PhA was significantly reduced in 
malnourished versus well-
nourished patients. 










Total: 5.04° ± 0.88°, 
SGA-A: 5.25° ± 0.76°, 
SGA-B+C: 4.73° ± 0.96°, 
p=0.0009 
Optimal cut-off point 
(4.733°): 




PhA was significantly reduced in 
malnourished versus well-
nourished patients. 








SGA-A: 5.25° ± 0.76°; 





PhA was significantly reduced in 
malnourished versus well-
nourished patients. PhA was 
negatively correlated with 
worsening SGA score. 
(Mulasi et al. 
2016) 
PG-SGA N/A 
PG-SGA-A: 5.5° ± 0.96°  





No significant difference in PhA 
between well-nourished and 
malnourished patients. 
PhA was negatively correlated 









  SGA-A: 5.3°  
  SGA-B+C: 4.2°, p<0.001 
Male:  
  SGA-A: 5.4° ± 1.0°  
  SGA-B+C: 4.5° ±1.1°, 
p<0.05 
Female:  
SGA-A: 5.1° ± 0.8° 
SGA-B+C: 4.0° ±1.1°, 
p<0.05 
- 








Total: 4.59° ± 1.12° 
   Male: 4.70° ± 1.17°, 




SPhA and SGA-B:  
OR 0.633 [(95% CI 
(0.504-0.794)], p<0.0001 
SPhA and SGA-C:  
OR 0.449 [(95% CI 
(0.337-0.597)], p<0.0001 
- 
Patients with a high SPhA had 
1.5 times lower odds of being 
classified as moderately 
malnourished and 2.2 times 
lower odds of being classified as 
severely malnourished than the 




















Median PhA/SPhA:  
5.95° ± 1.00°; -1.04 ± 0.98 
SD 
Median PG-SGA score: 4 
± 4 
PhA and PG-SGA (5.9°): 
ĸ=0.25 
AUC=0.72 [95% CI 
(0.61-0.83)]  
PhA and PG-SGA 
categorical (5.4°): ĸ=0.26 
AUC=0.84 [95% CI (0.69-
0.99)] 
Fair agreement between SPhA 
and PG-SGA, and SPhA and 
PG-SGA categorical. 
Optimal PhA cut-off points 
using PG-SGA and PG-SGA 
categorical as gold standard were 
<5.9° and <5.4°, respectively. 
Renal Disease 
(Guerra et al. 
2015) 
SGA N/A 
SGA-A: 6.4° ± 0.7° 
SGA-B: 5.6° ± 0.9° 
SGA-C: 5.3° ± 0.6°, 
p<0.01 
   SGA-A versus SGA-B, 
p<0.05 
   SGA-A versus SGA-C, 
p<0.05 
   SGA-B versus SGA-C, 
NS 
- 
PhA was significantly reduced in 
mildly and severely 
malnourished patients as 
compared to well-nourished 
patients, but, there was no 
significant difference between 
mildly and severely 
malnourished patients. 
(Passadakis 
et al. 1999) 
SGA N/A 
Male: PhA=5.06° ± 1.3° 
Females: 4.79° ± 1.4°, 
p=0.56 
SGA-A: 5.41° ± 1.15°, 
SGA-B: 4.62° ± 1.21°, 
SGA-C: 3.5° ± 1.53° 
   A versus B, p=0.087 
 
No significant difference in PhA 
between males and females.  
PhA was significantly reduced in 
mildly and moderately 
malnourished patients as 
compared to well-nourished 
patients, however, there was no 





   A versus C, p=0.021 
   B versus C, p=0.193 
Spearman's rank test: 
R=0.48, p=0.0048 
between mildly and moderately 
malnourished patients. PhA was 
negatively correlated with 
worsening SGA-score. 
(Gu et al. 
2008) 
SGA N/A 
SGA-A: 4.79° ± 1.04°; 
SGA-B+C: 3.83° ± 0.86°, 
p<0.001 
 
PhA was significantly reduced in 
malnourished versus well-
nourished patients. 




   SGA-A: 6.32° ± 1.37°;  
   SGA-B+C: 4.56° ± 0.91°, 
p<0.001                                                                          
Female:  
   SGA-A: 5.76° ± 1.26°;  
   SGA-B+C: 4.02° ± 0.72°, 
p=0.009 
CAPD:  
   SGA-A: 4.82° ± 0.78°;  
   SGA-B+C: 4.05° ± 0.49°, 
p=0.016 
HD:  
  SGA-A: 6.76° ± 1.06°;  





PhA was significantly reduced in 
malnourished versus well-
nourished patients in each sex 
group and in CAPD and HD 
groups. 
In total sample, PhA was 










coefficient of the repeated 
measures model in time: 
Male: ß=0.05 (0.02 SE), 
p=0.03 
Female: ß=0.39 (0.11 SE), 
p=0.002 
*adjusted for age and 
dialysis vintage 
 
1-unit increase in 7p-SGA was 
significantly associated with an 
increase of 0.05° and 0.39° in 












correlation coefficient:  
rs=-0.43, p≤0.01 
Lower quartile cut-off: 
Sensitivity: 67% 
Specificity: 78% 
<10th percentile cut-off: 
Sensitivity: 91% 
Specificity: 33% 
PhA was negatively correlated 
with worsening SGA-score. 
(Rimseviciu






Multivariate analysis:  
OR 3.69 [95% CI (1.59-
8.62)], p=0.002 
Optimal PhA cut-offs: 
SGA-B: <25th percentile  
AUC 0.70 [95% CI 
(0.60-0.81)], P=0.01) 
SGA-C: <15th percentile  
AUC 0.74 [95% CI 
(0.62-0.85)], P=0.005) 
Mild malnutrition was most 
accurately identified by PhA 
<25th percentile. Severe 
malnutrition was most accurately 
identified by PhA <15th 
percentile. 
Patients with a higher PhA had 
3.68 times lower odds of being 
classified as malnourished than 












SGA-A: 6.76° ± 1.4° 
SGA-B+C: 6.2° ± 1.7°, 
p=0.10 
Multivariate analysis:  
OR = 0.42, p=0.011 
 
No significant difference 
between malnourished and well-
nourished patients. 
Patients with a higher PhA had 
2.4 times lower odds of being 
classified as malnourished than 
the odds of being identified as 
well-nourished. 
(de Oliveira 









Total: 6.19° ± 1.33° 
Male: 6.70° ± 1.23°; 
Female: 5.73° ± 1.27°, 
p=0.005 
Linear correlation:  
Adapted SGA and PhA:  
r=-0.533, p<0.001 
PG-SGA and PhA:  
r=-0.453, p<0.001  
SGA and PhA: ĸ=0.316 
PhA was significantly higher in 
males versus females. 
Moderate agreement between 
PhA and adapted SGA. 
PhA was negatively correlated 
with worsening adapted SGA 
and PG-SGA scores. 
AUC: area under the curve; CAPD: continuous ambulatory peritoneal dialysis; HD: hemodialysis; NS: not significant; OR: odds 
ratio; PhA: phase angle; ROC: receiver operator characteristics; SE: standard error; SGA-A: well-nourished; SGA-B: mild-





3.4.1 Liver Disease 
Four studies included participants with liver disease, two in chronic liver disease, one in 
pre-transplant (Tx) patients and one in post-Tx patients. Two additional studies were 
identified which assessed both SGA and PhA, however, all patients were assessed as 
SGA-A which did not allow for any direct comparison between SGA-score and PhA. 
Thus, these two articles were not included in this systematic review (Nunes et al. 2016; 
Saxena, Sharma, and Gupta 2016).  
Two studies aimed to identify malnutrition using predetermined PhA cut-offs. Wagner et 
al. (2011) found a PhA cut-off of <5° in individuals post liver Tx did not correlate with 
SGA, and malnutrition was underestimated by SGA compared with PhA cut-offs. While 
Bakshi and Singh (2016) reported a moderate agreement between SGA and a PhA cut-off 
of <4.4° in hospitalized, end-stage liver disease patients. Additionally, Peres et al. (2012) 
found that PhA was significantly higher (p=0.005) in well-nourished patients compared 
to malnourished patients with chronic lung disease (CLD). Whereas, in a small study of 
eligible transplant patients with cirrhosis, no significant difference (p>0.05) was found 
between the mean PhA of well-nourished and malnourished patients (Liboredo et al. 
2015).  In summary, an association between PhA and SGA within liver disease patients is 
not clear. Although a trend toward decreasing PhA with worsening malnutrition exists, 
most studies found no correlation between PhA and SGA.  
3.4.2 Hospitalized Patients  
Nine studies involved hospitalized patients with a variety of clinical conditions. In 
preoperative GI patients, Barbosa-Silva et al. (2003) found a moderate agreement 
(ĸ=0.39) between SGA and a PhA cut-off of <5.0°,  however, optimal cut-offs of 6.3° 
and 5.9° in males and females, respectively, had the best balances of sensitivity and 
specificity. Using a SPhA cut-off of <-1.65 SD, Meireless et al. (2012) found a weak 
agreement in females and a moderate agreement in males between SGA and SPhA. Two 
studies used a SPhA of <-0.8 SD. Cardinal et al. (2010) found a moderate agreement 





total sample and each sex-group. As well, Scheunemann et al. (2011) determined an 
optimal SPhA cut-off of <-0.63 SD.  
In medical, surgical and trauma patients, Kyle et al. (2012) determined an optimal PhA 
cut-off of <5.0° for men and <4.6° for women. Using these cut-offs, Kyle et al. (2013) 
found that the relative risk of low PhA increased with worsening malnutrition and Guerra 
et al. (2015) reported a 60.5% agreement with PG-SGA in both long and short stay 
hospitalized patients. In GI, hepatology, endocrinology, cardiology and general surgery 
patients, Norman et al. (2008) found that PhA was significantly reduced with worsening 
nutrition status (p<0.05). Stobaus et al. (2012) found reduced SPhA with worsening 
nutrition status. Overall, the body of research in hospitalized patients shows a significant 
reduction in PhA and/or SPhA with worsening malnutrition assessed using SGA. Despite 
this, agreement between the two methods ranged from weak to moderate as a variety of 
different PhA and SPhA cut-offs were used.  
3.4.3 Oncology 
Eleven studies were identified in oncology patient populations. Diagnoses included 
pancreatic cancer, gastric cancer (GC) and colorectal cancer (CRC), neuroendocrine 
neoplasia, and head and neck cancers (HNC). In patients with pancreatic cancer, Gupta et 
al. (2004) found a non-significant weak negative correlation between PhA and SGA (r=-
0.26, p=0.10). Gupta et al. (2008) found that median PhA of well-nourished patients was 
significantly greater (p=0.005) than that of malnourished patients in advanced CRC 
patients. Authors were only able to determine an optimal PhA cut-off of <5.9° in males. 
Vicente et al. (2013) found a significant association between malnutrition identified using 
PG-SGA and a PhA cut-off of <5.1° (p=0.041) in patients with active GC and CRC, and 
those tumor free for >3 months. Mauricio et al. (2013) found a weak agreement between 
SGA and SPhA in CRC patients, and only a significant difference in SPhA between the 
well-nourished and severely malnourished group (p<0.05). da Silva et al. (2013) also 
found a weak agreement between SGA and a SPhA cut-off <-1.65 SD in esophageal and 





Three studies were completed in HNC patients. Malecka-Massalska et al. (2016) found 
that PhA was significantly higher in well-nourished patients than in malnourished 
patients (p=0.0009) and an optimal cut-off of 4.733° was determined. Wladysiuk et al. 
(2016) also found significant difference between PhA in well-nourished and 
malnourished patients (p=0.0009), and PhA was found to be negatively correlated with 
SGA (r= -0.35, p=0.0022). Whereas, Mulasi et al. (2016) found no significant difference 
between PhA in well-nourished patients and malnourished patients (p=0.62) however, 
had a negative correlation of r=-0.35 (p<0.01).  
Maasberg et al. (2017) assessed malnutrition in patients with neuroendocrine neoplasia 
using SGA and PhA. Mean PhA was significantly higher (p<0.001) in the well-nourished 
group as compared to the malnourished group and continued to be significant when 
stratified by sex (p<0.05). Norman et al. (2010) studied the relationship between SPhA 
and SGA in patients with cancerous tumors. SPhA had a strong positive effect on SGA-B 
(p<0.0001), and SGA-C (p<0.0001). Using a SPhA cut-off <-1.65 SD, Motta et al. (2015) 
found fair agreement between SPhA and PG-SGA, and SPhA and PG-SGA categorical. 
An optimal PhA cut-off of <5.9° was determined using PG-SGA as the reference method, 
and <5.4° using PG-SGA categorical as the reference method. Articles with a broad range 
of cancer diagnoses were identified in our search.  Although studies reported significant 
agreements between PhA and/or SPhA with SGA, strengths of agreements ranged from 
fair to poor. 
3.4.4 Renal Disease 
Nine studies included participants with renal disease, including predialysis chronic 
kidney disease (CKD), continuous ambulatory peritoneal dialysis (CAPD) patients and 
hemodialysis (HD). Guerra et al. (2015) found a significant difference in PhA between 
well-nourished and malnourished groups (p<0.05), but not between mildly and severely 
malnourished groups (p>0.05) in pre-dialysis patients with Stage II-CKD. Two studies 
evaluated PhA in patients on CAPD. One study by Gu et al. (2008) found that PhA was 
significantly higher in well-nourished as compared to malnourished patients (p<0.001). 
While Passadakis et al. (1999) found that PhA was only significantly different between 





(r=0.48, p=0.0048) between SGA and PhA. Enia et al. (1993) found that PhA was 
significantly higher in well-nourished patients than in malnourished patients in both HD 
and CAPD patient groups with a significant negative correlation of r=-0.58 between SGA 
and PhA, (p<0.001). In HD patients, Santin et al. (2017) found that for every 1-unit 
increase in 7p-SGA PhA (improved nutritional status) was associated with an increase of 
0.05° in males and 0.39° in females, respectively. 
Four studies analyzed PhA cut-offs in HD patients. Maggiore et al. (1996) found that a 
PhA cut-off of <25th percentile used to identify severe malnutrition had a 67% sensitivity 
and 78% specificity. However, a lowered cut-off of <10th percentile had an improved 
sensitivity of 91% but a reduced specificity of 33%. Rimsevicius et al. (2016) found that 
moderately and severely malnourished patients were most accurately identified by 
adjusted PhA cut-offs of <25th and <15th percentile, respectively. Vannini et al. (2009) 
used a PhA cut-off of <6.4° and found no significant difference between mean PhA of the 
well-nourished and malnourished groups (p=0.10) but had an odds ratio of 0.42 
(p=0.011). de Oliveira et al. (2010), found that PhA had a significant negative linear 
relationship with QSGA and PG-SGA, and a moderate agreement with SGA using a PhA 
cut-off of <5.0°. Although no studies used SPhA in their analyses, the majority of studies 
in the renal disease population reported significant trends of decreased PhA with 
worsening malnutrition.  
3.4.5 Quality Assessment 
Evidence quality was assessed by both GRADE Guidelines and the QUADAS-2 tool. 
Results of the quality assessment using the GRADE guidelines are shown in Table 3. 





Table 3 Summary of Findings 
Bioelectrical phase angle compared to Subjective Global Assessment as an 
indicator of malnutrition  
Patient or Population: acute or chronically ill adult patients 
Setting: inpatient and outpatient 
Intervention: Measurement of phase angle 







Quality and Justification 




























Renal Disease  
749 + 272 controls  




1Inconsistency in results 
2Risk of bias: no sex comparison, minimal to no use of SPhA 
3Large magnitude of effect: significant difference in PhA between well-nourished and 
malnourished patients  








Figure 3 QUADAS-2 Results. 
The proportion of studies with low, high and unclear risk of bias and concerns regarding 
applicability between the index test (PhA) and SGA are shown according to QUADAS-2 
domains. a) Overall, 61% of studies had high risk of bias of the index test, PhA, and 9% 
of studies had high concerns for the applicability of the index test, b) Liver disease: Due 
to the lack of any PhA standardization methods, 100% of the articles reviewed had a high 
risk of bias of the index test, PhA c) Oncology patients: 34% of studies had high risk of 
bias of the index test. d) Hospitalized patients - 64% of studies had high risk of bias in 
the use of PhA. Two studies (22% of studies) had concerns related to the applicability of 
the index test due to exclusion of participants where PhA measurement and SGA would 





obtain anthropometric parameters due to patients being bedridden. e) Renal disease - 
Only a third of articles (Figure 3e) attempted to control for confounding factors through 
testing for sex differences or analyzing results by sex, therefore 67% of studies had high 
risk of bias of the index test. 11% of studies had concerns related to the applicability of 
the index test due to exclusion of participants where PhA measurement and SGA would 
have been appropriate. 
 Discussion 
This study aimed to evaluate the relationship between bioelectrical phase angle and 
malnutrition severity as measured by the Subjective Global Assessment in acute or 
chronically ill adults. Many studies used different PhA cut-offs, for example, sample 
median, lower quartile or cut-offs determined from previous studies which may not be 
translatable to all disease states. As the full biological meaning of PhA is not understood 
it would be difficult to predict how PhA may vary by disease even with controlling for 
confounding factors such as nutrition status, weight, age or gender. It is difficult to say 
with certainty that PhA cut-offs determined within one disease state, or based on non-
nutritional parameters such as survival, are appropriate in all clinical situations. 
Therefore, the overall evidence quality determined in this systematic review received a 
grade of Low. 
Many nutritional assessment tools exist; however, their use within specific disease 
populations can be limited. Within liver disease, complications such as fluid retention and 
hypoproteinemia associated with hepatic deterioration can confound nutritional 
assessment techniques such as BIA, biochemical markers, and BMI (Tynan and Hasse 
2004). Use of SGA in CLD is recommended by the European Society for Parenteral and 
Enteral Nutrition to screen for malnutrition in liver disease including alcoholic 
steatohepatitis, cirrhosis, surgery, and transplantation (Plauth et al. 2006). A recent 
review also identified SGA as a tool to use in nutritional assessment in liver cirrhosis 
(Tandon et al. 2017). Despite its acknowledged limitations in individuals with ascites, 
European Society for Parenteral and Enteral Nutrition recommends PhA to quantify 
undernutrition in cirrhosis, and in liver transplantation and surgery and PhA is said to be 





Interestingly, in these guidelines, the use of SGA in CLD received an evidence grade of 
C, while the use of PhA received a grade of B. Additionally, clinical practice guideline 
recommendations, evidence quality of the use of PhA in malnutrition assessment received 
the lowest grade.  
Hospital malnutrition is a well-established issue (Butterworth 1974), and has been 
associated with pressure ulcers, infection, impaired wound healing, increased length of 
hospital stay and readmission risk, all of which create a greater burden on health care 
costs and, ultimately, quality of life for patients (Tappenden et al. 2013). The American 
Society for Parenteral and Enteral Nutrition and European Society for Parenteral and 
Enteral Nutrition have recommended routine use of nutrition screening to identify 
malnutrition in hospitalized patients, including using SGA (Kondrup et al. 2003; Mueller 
et al. 2011). Currently, no published guidelines have identified the use of PhA in 
malnutrition screening or assessment.  
Many elements of kidney disease such as fluid retention can complicate clinical 
assessments and jeopardize nutrition (de Oliveira et al. 2010). The utility of PhA and 
other BIA measures in dialysis patients is limited due to overhydration pre-dialysis and 
body water compartments not yet in steady state immediately post-dialysis. The National 
Kidney Foundation’s Kidney Dialysis Outcomes Quality Initiative clinical guidelines 
have identified the need for frequent nutrition assessment and recommend SGA as a valid 
and clinically useful tool in the overall nutritional assessment of non-dialyzed and 
dialyzed individuals (Johansen et al. 2001). The National Kidney Foundation’s Kidney 
Dialysis Outcomes Quality Initiative guidelines recommend The CANADA-USA 
Peritoneal Dialysis Study Group Study’s 7p-SGA (Churchill, Taylor, and Keshaviah 
1996) as the preferred SGA technique. The National Kidney Foundation’s Kidney 
Dialysis Outcomes Quality Initiative identify valid methods of protein-energy 
malnutrition through anthropometric analysis, however, use of BIA in nutrition 
assessment is not mentioned in these guidelines. More recently, the 2010 Chronic Kidney 
Disease (CKD) Evidence-Based Nutrition Practice Guideline (The American Dietetic 
Association 2010) from Academy of Nutrition and Dietetics concluded that any valid 





such as dual energy x-ray absorptiometry or BIA, are appropriate in CKD. However, as 
no reference standard for assessing body composition in CKD patients has been 
established, no one test has been shown to be superior to another with respect to assessing 
body composition.  
Nutrition status in oncology patients can be affected by surgery, radiation and 
chemotherapy treatment as well as the pathophysiology of cancer itself (Lis et al. 2012). 
Prevalence of malnutrition is estimated to range between 50-80% depending on cancer 
diagnosis (Lis et al. 2012). Clinical practice guidelines have recommended the use of 
SGA and PG-SGA in the oncology population (August, Bozzetti, and Huhmann 2009; 
Fearon et al. 2011). As well, in their review of available tools within the adult oncology 
population, the Academy of Nutrition and Dietetics’ Oncology Expert Work Group 
identified both the SGA and PG-SGA as valid and reliable tools in nutrition diagnosis 
within ambulatory and acute care settings (Nutrition and the Adult Oncology Patient 
2013). No published guidelines have identified use of PhA in malnutrition screening or 
assessment.  
Standardizing PhA with reference values for healthy populations may work to resolve 
this issue of PhA variation through accounting for individual variations from population 
norms (Norman et al. 2010). Thus, SPhA allows for results that are translatable and 
comparable between studies and disease states. Of the 33 articles identified in this 
systematic review, only nine used SPhAs.  Despite SPhA providing greater rigor than 
absolute values of PhA alone, variation can still exist based on the reference data used. 
For example, population norms determined in a German population (Bosy-Westphal et al. 
2006) may be different than those determined in a Brazilian population (Barbosa-Silva, 
Barros, and Larsson 2008). Population norms can be standardized in a number of 
different ways. For instance, most published norms are presented in age- and sex-
stratified groups, with fewer studies also including or ethnicity. Future research should 
make use of a SPhA, however, published data on PhA norms reflecting more diverse 
populations is needed. Thus, careful consideration is necessary when choosing 





Only six studies attempted to determine an ideal PhA or SPhA cut-off to diagnose 
malnutrition using SGA as the reference standard. Within hospitalized patients, one study 
identified a SPhA cut-off of <-0.63 SD (Scheunemann et al. 2011), while two studies 
suggested gender-specific cut-offs of <6.3° in males and <5.9° in females (Barbosa-Silva 
et al. 2003), and <5.0° in males and <4.6°in females, respectively (Kyle, Genton, and 
Pichard 2013). Within cancer patients, suggested PhA cut-off values included <4.733° 
(Malecka-Massalska et al. 2016), <5.9° (Motta, Castanho, and Velarde 2015), <5.4° 
(Motta, Castanho, and Velarde 2015), and <5.9° ( Gupta et al. 2008) in males with 
progressive disease. Although other PhA and SPhA cut-offs exist, it is important to note 
that other cut-offs present in the literature may have been determined using non-nutrition 
related reference standards limiting their ability to accurately identify malnutrition. 
Limitations of SGA-derived PhA or SPhA cut-offs, such as their diagnostic accuracy, 
should not be overlooked. Additionally, we acknowledge that including only articles 
published in English can bias the results found in this systematic review.  
A limitation of using a single PhA or SPhA cut-off value is that it restricts an individual’s 
nutrition status into two binary categories: well-nourished or malnourished. Rather, 
nutrition status exists on a spectrum. One small study (n=20) identified in this review 
used two PhA cut-offs to classify patients into three categories; normal, borderline and 
abnormal (Bakshi and Singh 2016). However, no patients were identified as having 
borderline PhAs, therefore, no comparison was made between comparable SGA-B and 
borderline PhA groups. Thus, in addition to controlling for confounding factors using a 
SPhA, and carefully choosing an appropriate cut-off value, future research should attempt 
to identify varying degrees of malnutrition using multiple SPhA cut-offs.  
A major limitation of this review is attempting to find a meaningful relationship between 
two methodologies that may both be influenced by the operator. However, many studies 
have already used PhA as a nutritional marker to diagnose malnutrition despite its lack of 
validation. Therefore, it is important to comprehensively study the appropriateness of its 
use in both research and clinical practice. The current body of research indicates that PhA 
cannot independently identify malnutrition in disease, however, PhA or SPhA may show 





be able to detect more sensitive changes in nutrition status as compared to other nutrition 
assessment tools, which can be useful in assessing effectiveness of nutrition 
interventions. However, further research is needed to explore the relationship between 
nutrition status and PhA over time.  
 Conclusion 
Early identification of malnutrition or the risk of malnutrition is vital in order to provide 
appropriate nutrition therapy as preventing worsening malnutrition or correcting 
nutritional deficiencies can help improve overall nutritional status and prognosis. Thus, 
the idea of a simple, quick and objective measure to identify malnutrition is appealing. 
Although the results of this systematic review are sufficiently encouraging to warrant 
further research in utilizing PhA, we are not able to conclude that PhA can independently 
identify malnutrition in disease.    
Future research using PhA in nutritional assessment should focus on utilizing a 
standardized PhA. Additionally, further research should investigate the change in SPhA 
over time to determine if improvement or decline in nutritional status will affect SPhA. 
Within a clinical practice perspective, inclusion of SPhA in nutritional assessment can 
complement other nutrition assessment methods, as one method alone may not be 







Chapter 4  
4 Exercise Capacity and its Relationship with Body 
Composition and Nutrition Status in Patients with 
Interstitial Lung Disease 
 Abstract 
Background: Individuals with interstitial lung disease (ILD) are known to have 
diminished exercise ability. In ILD, neither the impact of body composition nor nutrition 
status on functional exercise capacity has been fully explored. The primary objective of 
this study was to explore the relationship between nutrition status and body composition 
parameters with exercise capacity in a cohort of patients with fibrotic ILD. Our second 
objective focused on assessing the appropriateness of surrogate markers of nutrition 
status in ILD patients. Methods: Seventy-eight patients diagnosed with fibrotic ILD were 
recruited from the ILD clinic in London, Ontario, Canada. Lung function was determined 
by % predicted forced vital capacity (%FVC). Exercise capacity was determined the 6-
minute walk distance (6MWD). Nutrition status was assessed using the validated 
subjective global assessment (SGA), standardized phase angle (SPhA) and impedance 
ratio z-score (z-IR). Body composition parameters fat-free mass index z-score (z-FFMI) 
and body fat mass index z-score (z-BFMI) were determined using bioelectrical 
impedance analysis. Results: A total of 57% of participants were moderately to severely 
malnourished according to SGA. z-FFMI (r=0.42, p=0.02) and SGA (r=0.49, p<0.01) 
were significantly associated with 6MWD independent of %FVC. Age [OR 1.1, CI 95% 
(1.01-1.25), p=0.04], low body mass index [OR 0.73, 95% CI (0.57-0.92), p=0.01], z-
FFMI [OR 0.34, CI 95% (0.17-0.68), p<0.01], z-BFMI [OR 0.39, CI 95% (0.17-0.91), 
p=0.03] were significantly associated with severe malnutrition (SGA-C). SPhA did not 
show to be a surrogate marker of nutrition status in our sample, however, mean z-IR was 
significantly greater in the severe malnutrition group compared to the well-nourished 
(p<0.01) and moderate malnutrition (p=0.04) groups. A higher z-IR significantly 
increased the odds of severe malnutrition [OR 2.75, 95% CI (1.27-6.03), p=0.02]. 
Conclusion: Decreased z-FFMI and SGA-C independent of lung function were 





greater in severe malnutrition versus the well-nourished group indicating worsened cell 
health in severe malnutrition.   
 Introduction 
Individuals with interstitial lung disease (ILD) are known to have limited exercise ability 
(Mendes et al. 2015), which can significantly impact their ability to participate in normal 
activities of daily living, compromising their quality of life (Hansen and Wasserman 1996; 
Mendes et al. 2015). Diminished exercise capacity in ILD is multifaceted including 
pathophysiological factors such as impaired gas exchange, altered respiratory mechanics, 
limited pulmonary circulation and peripheral muscle dysfunction (Holland et al. 2008; 
Raghu et al. 2011).  
The six minute walk test is a reliable and validated tool in ILD patients routinely used to 
measure functional exercise capacity, or in other words, the functional level of exercise of 
everyday physical activities (Du Bois et al. 2011; Eaton et al. 2005; Lederer et al. 2006; 
Serajeddini, Rogliani, and Mura 2018). A decline in 6-minute walk distance (6MWD) 
predicts both poor survival and mortality in patients on a lung transplant waitlist (Du Bois 
et al. 2011; Lederer et al. 2006). The 6MWD has high prognostic value as it is independent 
from lung function (Serajeddini, Rogliani, and Mura 2018).  
In other chronic lung diseases, such as chronic obstructive pulmonary disease (COPD), 
poor nutrition status has a negative effect on exercise capacity and muscle dysfunction 
(Sabino, Silva, and Brunetto 2010; Shan et al. 2015). As well, nutrition intervention and 
education have the potential to improve exercise capacity in COPD patients (Hill, 
Vogiatzis, and Burtin 2013; Steiner et al. 2003). However, in ILD, no studies have assessed 
the relationship between nutrition status and exercise capacity, nor has the potential for 
nutrition intervention in ILD as part of pulmonary rehabilitation been established. 
Components of overall nutrition status, such as body mass index (BMI), and more recently 
lean body mass, have been shown to be predictors of survival in patients with idiopathic 
pulmonary fibrosis (IPF), a common component of ILD. In ILD, neither the impact of low 





The primary objective of this study was to explore the relationship between nutrition status 
assessed using the subjective global assessment (SGA), and body composition parameters 
assessed using bioelectrical impedance analysis (BIA) with exercise capacity in a cohort 
of patients with fibrotic ILD. Since obtaining SGA requires trained personnel, who may 
not be readily available as part of standard ILD care, our second objective focused on 
assessing the appropriateness of surrogate markers of nutrition status, such as standardized 
phase angle (SPhA) and impedance ratio (IR), in ILD patients.    
 Methods 
4.2.1 Study Population 
In this cross-sectional study, patients diagnosed with fibrotic ILD (n=78) were recruited 
from the ILD clinic in London, Ontario, Canada. Inclusion criteria included ambulatory 
patients over 18 years of age attending an ILD clinic. Patients were excluded according to 
the following criteria: inability to provide consent due to communication issues (cognitive 
and motor), presence of cardiac implantable electrical devices, non-stable ILD patients 
defined as those with infections and/or fever, admitted to hospital in the previous month, 
presence of an unstable co-morbid illness or combined pulmonary fibrosis and emphysema 
(CPFE). The study protocol was approved by the Western University Research Ethics 
Board (protocol n. 104028).  
4.2.2 Diagnosis and Disease Severity 
The presence of fibrotic ILD was defined based on high-resolution chest computed 
tomography scan and compatible pulmonary function tests. After excluding all known 
causes of ILD, IPF was diagnosed based on clinical and radiographic criteria, and when 
necessary, on surgical lung biopsies, followed by multi-disciplinary discussion (Flaherty 
et al. 2004; Raghu et al. 2018). The diagnosis of fibrotic ILD other than IPF was based on 
clinical presentation, laboratoristic, bronchoscopic, radiographic investigations and, when 
indicated (e.g. non-specific interstitial pneumonia cases), surgical lung biopsies. Patient 





and six-minute walk tests. Pulmonary function tests and six-minute walk tests were 
performed as part of patients’ standard of care and according to the American Thoracic 
Society guidelines (American Thoracic Society (ATS) 2002; Standardization of 
Spirometry, 1994 Update. American Thoracic Society. 1995).  
4.2.3 Bioelectrical Impedance Analysis: Body Composition 
Estimates of fat-free mass index (FFMI) and body-fat mass index (BFMI) were determined 
using dual frequency BIA (BodyStat 1500MD, UK). BIA is an easy and convenient bedside 
tool validated in a variety of clinical settings (Fuller, Sawyer, and Elia 1994; Ghosh et al. 
1997; Steiner et al. 2002) whereby a 50 kHz electrical current is passed through the body 
via two electrodes placed on the surfaces of the right hand and foot measured at fixed 
frequencies (BodyStat 2017). FFMI and BFMI were calculated using estimates of fat-free 
mass and body fat mass obtained using BIA according to the following equations: FFMI= 
fat-free mass (kg) / [height (m)]2, and BFMI= body fat mass (kg) / [height (m)]2, 
respectively. FFMI and BFMI are affected by factors such as sex and age, therefore, FFMI 
and BFMI z-scores (z-FFMI and z-BFMI) were calculated to account for these factors 
based on population norms (Kyle et al. 2001). A z-score of zero indicates a value equal to 
the population mean of healthy subjects, a positive z-score indicates a value is greater than 
the population mean, and a negative z-score indicates a value less than the population 
mean. z-FFMI and z-BFMI were calculated according to the following equation: z-score = 
(x - xpopulation mean)/ standard deviationpopulation (SD).  
4.2.4 Nutrition Assessment  
The gold standard of nutrition assessment is the SGA. The SGA collectively considers diet 
and weight history, disease history as it relates to catabolism, nutrition-related functional 
status, gastrointestinal issues, and a physical examination to detect clinical signs of muscle 
wasting, subcutaneous fat loss and edema taken all together to determine overall nutrition 
status (Detsky et al. 1987). SGA categories, A, B and C, represent well-nourished, 
moderate malnutrition or suspected of being malnourished, and severe malnutrition, 





Detsky et al. 1987). SGA was completed according to the method outlined by Detsky et al. 
(1987) (Detsky et al. 1987)(Detsky et al. 1987)(Detsky et al. 1987)(Detsky et al. 
1987)(Detsky et al. 1987)and was performed by a registered dietitian (SR).  
4.2.5 Surrogate Markers of Nutrition Status: Phase Angle 
and Impedance Ratio  
PhA and IR are raw measures of BIA thought to be surrogate markers of nutrition status in 
various clinical populations (Kuchnia et al. 2017; Rinaldi et al. 2019). PhA is related to the 
resistance and reactance of a current as it travels through the body at a constant frequency 
of 50kHz (PhA = arctan(reactance/resistance)). The IR is the ratio of impedances at 200 
kHz and 5 kHz. A lower PhA or an IR closer to 1 indicates poorer cellular health. Age, sex 
and BMI can affect raw values of PhA and IR; therefore, to control for these confounding 
factors, a standardized phase angle (SPhA) and IR z-score (z-IR) were calculated using 
population norms (Bosy-Westphal et al. 2006; Kuchnia et al. 2017) according to the z-
score equation noted above.   
4.2.6 Statistical Analysis 
Quantitative variables are expressed as mean ± standard deviation (SD) and qualitative 
variables are displayed as frequencies. The Shapiro-Wilk test was used to determine 
normality of variables. To test for significant across groups a one-way ANOVA was used 
with parametric data and the Kruskal-Wallis test was used with nonparametric data. To test 
for between group significance, the independent samples t-test was used with parametric 
data and the Mann-Whitney U test was used with nonparametric data. The Pearson’s 
correlation coefficient (r) was used to determine the strength and direction of two 
continuous parametric variables, and the Spearman’s rho (rs) was used for comparison of 
nonparametric continuous variables or comparison of a continuous and categorical 
variable. Correlation coefficients were interpreted as previously suggested (Cohen 1988); 
Pearson’s correlation coefficient: r = 0.10-0.29 = a small; r = 030-0.49 = medium; r = 0.50-
1.00 = large; Spearman’s rho,:  rs < .16 = too low to be meaningful; rs = 0.16-0.29 = weak 





= 0.9-1 = very strong. Stepwise multiple regression analysis selected the independent 
contributors of 6MWD. Multinomial logistic regression was used to determine odds ratios 
and 95% confidence intervals among factors with SGA groups. P-values <0.05 were 
regarded as significant. Statistical analysis was performed with IBM® SPSS® Statistics 
Version 26 software package. 
 Results  
Sociodemographic patient characteristics and fibrotic ILD diagnoses are shown in Table 
4. Anthropometric and nutrition status data are displayed in Table 5. 43% of participants 
were identified as SGA-A (well-nourished), 49% were SGA-B (moderately 
malnourished), and the remaining 8% were SGA-C (severely malnourished). Raw values 
of PhA and IR were significantly greater and significantly lower in males, respectively. 
Mean SPhA was -0.44 ± 1.08 SD, and mean z-IR was 5.73 ± 1.52. 6MWD was not 












Mean ± SD  
or Frequency (%) 
Age (years) 68.4 ± 10.0 
Sex   
   Male 38 (48.7) 
   Female 40 (51.3) 
Diagnosis   
Idiopathic pulmonary fibrosis 36 (46.2) 
Drug-induced toxicity 10 (12.8) 
Rheumatoid arthritis related ILD 8 (10.3) 
Non-specific interstitial pneumonia 8 (10.3) 
Chronic hypersensitivity pneumonitis 5 (6.4) 
Unclassifiable ILD  4 (5.1) 
Scleroderma-related ILD 3 (3.8) 
Sarcoidosis (stages III-IV) 2 (2.6) 
Vasculitis-related ILD 2 (2.6) 
Medication usage   
Proton pump inhibitors 43 (55.1) 
Pirfenidone 16 (20.5) 
N-acetylcysteine 12 (15.4) 
Mycophenolate mofetil 9 (11.5) 
Nintedanib 2 (2.6) 
Pulmonary Function and Exercise Capacity 
FEV1 (% predicted) 75.1 ± 18.9 
FVC (% predicted) 71.2 ± 19.5 
DLCO (% predicted) 40.6 ± 17.1 
6MWD (m) 
     Male 
     Female 
335.6 ± 109.8 
335.4 ± 120.2 
335.8 ± 100.5 
Continuous variables are expressed as mean ± standard 
deviation. ILD, interstitial lung disease; FEV, forced expiratory 
volume; FVC, forced vital capacity; DLCO, diffusing capacity 


















Results of the bivariate correlation analysis are shown in Table 6. The relationship 
between age, z-FFMI, %FVC and SGA with 6MWD was statistically significant 
(p<0.05). The relationships between 6MWD and sex, BMI, and z-BFMI were not 
statistically significant. Variables significantly correlated with 6MWD were then tested 
together in a stepwise regression analysis displayed in Table 7. As SGA accounts for loss 
of fat-free mass in its assessment, z-FFMI and SGA were analyzed in separate models. 
When controlling for lung function using %FVC, z-FFMI (β=15.68, p=0.02) and SGA  
(β=-67.82, p=0.01) were still significant independent predictors of exercise capacity 
(Table 7).  
  
Clinical Characteristics 
Mean ± SD  
or Frequency (%) 
Anthropometry 
BMI (kg/m2) 30.8 ± 7.3 
z-FFMI (SD) 0.39 ± 1.98 
   z-BFMI (SD) 2.27 ± 2.15 
Nutritional Indices  
 
SGA-A (well-nourished) 34 (43.6)  
SGA-B (moderate malnutrition) 38 (48.7) 
SGA-C (severe malnutrition) 6 (7.7) 
Phase angle (°) (n=77)  
Male 5.55 ± 1.15⸹ 
Female 4.90 ± 0.81 
Standardized phase angle (SD) -0.44 ± 1.08 
Impedance ratio (n=65)  
    Male 0.881 ± 0.813† 
    Female  0.899 ± 0.028 
Impedance ratio z-score (SD) 5.73 ± 1.52 
Continuous variables are expressed as mean ± standard 
deviation. BMI, body mass index; SD, standard deviation; 
SGA, subjective global assessment; z-BFMI, body-fat mass 
index z-score; z-FFMI, fat-free mass index z-score. 
⸹ Significant difference between sexes of p<0.01. 





Table 6 Relationship between physiological, clinical variables and 6-minute walk 
distance. 
Variable r p-value 
Age 0.31 0.01 
%FVC  0.30 0.01 
BMI 0.03 0.79 
z-FFMI 0.28 0.02 
 rs p-value 
Sex  -0.04 0.74 
z-BFMI  0.00 0.99 
SGA -0.38 <0.01 
BMI, body mass index; %FVC, percent 
predicted forced vital capacity; r, 
Pearson’s correlation coefficient; rs, 
Spearman’s rho; SGA, subjective global 
assessment; z-BFMI, body-fat mass 
index z-score; z-FFMI, fat-free mass 
index z-score. 
Table 7 Linear regression: predictors of 6-minute walk distance. 





1.67 0.29 0.36-2.98 0.01 





1.71 0.30 0.46-2.97 <0.01 
SGA -67.82 -0.39 -106.09-(-29.54) <0.01 
B; unstandardized beta coefficient; β, standardized beta coefficient; %FVC, percent 
predicted forced vital capacity; r, Pearson’s correlation coefficient; SGA, subjective 
global assessment, z-FFMI, fat-free mass index z-score.  
Mean SPhA was not significantly different across SGA groups; however, mean z-IR was 
significantly greater in the SGA-C group versus the SGA-A (p<0.01) and SGA-B 
(p=0.04) groups (Table 5). No variables significantly affected the odds of moderate 
malnutrition (SGA-B) compared to the well-nourished group (SGA-A) (Table 6). 
However, increased age [OR 1.10, 95% CI (1.01-1.25), p=0.04] and z-IR [OR 2.76, 95% 
CI (1.27-6.03), p=0.02] had increased odds of severe malnutrition (SGA-C) as compared 
to the well-nourished group (SGA-A). Increased z-FFMI [OR 0.34, 95% CI (0.17-0.68), 





(0.57-0.92), p=0.01] had decreased odds of severe malnutrition (SGA-C) as compared to 
the well-nourished group (SGA-A).  
Table 8 Mean SPhA and z-IR across SGA categories 
SGA Category SPha (SD) z-IR (SD)⸹ 
SGA-A (well-nourished) -0.07 ± 0.92 5.39 ± 1.34† 
SGA-B (moderate malnutrition) -0.78 ± 1.14 5.77 ± 1.55‡ 
SGA-C (severe malnutrition) -0.70 ± 1.21 7.40 ± 1.51 
A one-way ANOVA was used to compare means across groups. An independent sample 
t-test was used to compare between 2 groups. SD, standard deviation; SGA, subjective 
global assessment; SPhA, standardized phase angle; z-IR, impedance ratio z-score. 
⸹p=0.02 across groups 
†p<0.01 between SGA-A vs SGA-C 
‡p=0.04 between SGA-B and SGA-C 
 
Table 9 Multinomial logistic regression using SGA-A (well-nourished) as the reference 
category. 
Due to limited numbers in the SGA-C group, we were not able to test for association 
between nutrition status and medication use across all three SGA categories. Between 
well-nourished (SGA-A) and malnourished groups combined (SGA-B+C), no significant 
associations with medication use were found (data not shown). Additionally, z-FFMI was 
not significantly different between type of ILD medication groups (data not shown). 








OR (95% CI) OR (95% CI) p-value OR (95% CI) p-value 
Age  0.08 1 1.03 (0.98-1.08) 0.27 1.10 (1.01-1.25) 0.04 
%FVC 0.00 1 1.00 (0.98-1.03) 0.79 1.00 (0.96-1.05) 0.98 
BMI 0.18 1 0.97 (0.91-1.04) 0.41 0.73 (0.57-0.92) 0.01 
z-FFMI 0.21 1 0.80 (0.62-1.05) 0.11 0.34 (0.17-0.68) <0.01 
z-BFMI 0.12 1 0.91 (0.73-1.14) 0.41 0.39 (0.17-0.91) 0.03 
SPhA 0.05 1 0.68 (0.44-1.07) 0.10 0.60 (0.26-1.42) 0.25 
z-IR 0.14 1 1.21 (0.84-1.73) 0.32 2.76 (1.27-6.03) 0.02 
BMI, body mass index; CI, confidence interval;  OR, odds ratio;  %FVC, percent 
predicted forced vital capacity; R2, Nagelkerke’s R squared; SPhA, standardized phase 
angle; z-BFMI, body fat mass index z-score; z-FFMI, fat-free mass index z-score; z-IR, 





associations between nutrition status and diagnosis. However, of note, all 6 participants 
with severe malnutrition (SGA-C) had IPF.  
 Discussion 
This study examined the influence of body composition and nutrition status on exercise 
capacity in a cohort of patients with fibrotic ILDs. z-FFMI had a small relationship (r=0.28) 
with exercise capacity and was a significant predictor of exercise capacity when controlled 
for lung function. Worsened nutrition status had a low to moderate relationship (r=-0.38) 
with exercise capacity and was significantly associated with decreased exercise capacity 
independent of lung function.  
Muscle dysfunction may be worsened by factors such as age, inactivity and medication 
side effects (Nakazawa, Cox, and Holland 2017). In various ILDs, characteristics 
suggestive of muscle dysfunction related to inactivity or disuse have been observed. In a 
study of individuals with advanced ILD listed for lung transplant, muscle atrophy and 
weakness were seen in greater amounts in lower limb muscles of the quadriceps compared 
with upper limb muscles of the biceps (Mendes et al. 2015). Similarly, in fibrotic idiopathic 
interstitial pneumonias, quadricep muscle strength and endurance was significantly lower 
when compared to healthy controls (Mendoza et al. 2014). Interestingly, quadriceps muscle 
strength (r=0.44, p=0.03), but not total fat-free mass (r=-0.05, p=0.78), was shown to be a 
significantly correlated with 6MWD in the healthy controls (Mendoza et al. 2014). We 
demonstrated that z-FFMI, which controlled fat-free mass for height, age and sex, was 
significantly associated with exercise capacity independent of lung function. This is in line 
with previous data which suggests that muscle dysfunction as a result of disuse, or loss of 
muscle mass is indicative of exercise capacity (Holland et al. 2008; Raghu et al. 2011).    
Our results demonstrated a positive relationship between exercise capacity and nutrition. 
However, the influence of poor nutrition status on exercise capacity has not been well 
explored in ILD patients. In other chronic lung diseases, such as COPD, there appears to 
be a nutritional influence on exercise capacity. Specifically, normal versus low 6MWD 





Assessment® [OR 0.835 95% CI (0.735-0.908), p=0.005] in a group of COPD patients 
(Matkovic et al. 2017). Additionally, worsened nutrition status assessed using Mini 
Nutrition Assessment® was associated with worse dyspnea scores [OR 22.888, 95% CI 
(2.103-249.065), p=0.01], and lung function (FEV1/FVC ratio) [OR 0.898, 95% CI 
(0.826-0.977), p=0.012] (Mete et al. 2018). In ILD, nutrition support is included as a non-
exercise component in pulmonary rehabilitation programs (Nakazawa, Cox, and Holland 
2017). Specific nutrition recommendations, however, are limited in best practice 
guidelines (Raghu et al. 2011; Travis et al. 2013), and to the best of our knowledge, no 
studies have thoroughly explored the influence of poor nutrition status on diminished 
exercise capacity in ILD patients. Our results demonstrated a positive relationship 
between exercise capacity and nutrition status independent of lung function. With each 
SGA nutrition category improvement, we would expect 6MWD to increase by an average 
of 67.8 metres (β=-67.8). These promising results support the theory that nutritional 
rehabilitation as part of ILD care has the potential to improve functional exercise 
capacity.  
Few studies have assessed the prevalence of malnutrition in ILD. The majority of 
nutrition-related research in ILD has related to weight, BMI (Nishiyama et al. 2017) and 
FFMI (Nishiyama et al. 2017); however, no studies have assessed overall nutrition status 
comprehensively (Rinaldi, Mura, and Madill 2017). In this study, nutrition status was 
comprehensively assessed using the gold standard for nutrition assessment, SGA, which 
considers weight change, disease history, gastrointestinal and medication-related side 
effects and clinical characteristics such as edema, muscle wasting and fat loss (Detsky et 
al. 1987). We found that the majority of fibrotic ILD patients, according to SGA, were 
malnourished. Specifically, 49% of participants were moderately malnourished, and 8% 
were severely malnourished. Additionally, we found that increased age and various 
anthropometric measures such as BMI, z-FFMI and z-BFMI were associated with risk of 
severe malnutrition. As SGA captures factors such as weight loss, and signs of muscle 
wasting and subcutaneous fat loss using a clinical assessment, it is not surprising that 
greater values of BMI, and lean body mass and body fat were associated with lower odds 
of severe malnutrition. Interestingly, lung function assessed using %FVC was not 





Trained clinicians, such as dietitians, needed to perform the SGA may not be readily 
available as part of standard care, therefore surrogate markers of nutrition, such as PhA 
and IR, have been suggested in a number of different disease states (Kuchnia et al. 2017; 
Kyle et al. 2012; Kyle, Genton, and Pichard 2013; Malecka-Massalska et al. 2016; Ott et 
al. 1995; Plank and Li 2013). No studies to date have explored the relationship between 
PhA nor IR in ILD. In this study, we did not observe any significant differences in mean 
SPhA between SGA groups. However, a greater z-IR, which indicates poorer cellular 
health, had significantly increased odds of severe malnutrition as compared to the well-
nourished group. This is in line with previous research that suggests PhA may not be an 
appropriate standalone measure of nutrition (Rinaldi et al. 2019) and that IR may be a 
more robust measure of nutrition than PhA (Castillo Martinez et al. 2007; Plank and Li 
2013).  
Our study has some limitations. For example, the moderate sample size (N=78) limited 
our ability to assess the influence of specific diagnosis or medication use on nutrition 
status. Common ILD medications are known to have nutrition-related side effects. For 
example, anti-fibrotic agents are commonly associated with decreased appetite, nausea 
and diarrhea which would very likely affect an individual’s ability to maintain good 
nutrition. Therefore, further research is needed to thoroughly explore the risk of 
malnutrition with specific medication use and between ILD subtypes. Additionally, we 
acknowledge that ILD patients are a heterogeneous group, however, our study population 
included only fibrotic-ILDs which aimed to limit diagnosis-specific differences among 
our participants.  As this study was cross-sectional, we were not able to control for recent 
changes in disease severity. As such, future research should assess 6-month or 1-year 
changes in %FVC (Fernández Fabrellas et al. 2018) to control for worsening, stable or 
improved disease states. There is limited knowledge about the relationship of nutritional 
status on the clinical course of ILD, a potentially important implication on the outcome 
and quality of life of these patients. This research provides justification for the need of 
nutrition professionals in the standard of care of ILD patients. Future research should 
explore nutrition interventions, for example, aimed at improving lean body mass, and 
assess how improving nutrition can affect functional exercise capacity in patients with 






Decreased FFMI controlled for age and sex and severe malnutrition independent of lung 
function were significantly associated with exercise capacity in fibrotic ILD. SPhA was 
not significantly different between SGA groups, however, z-IR was significantly greater 
in the SGA-C (severe malnutrition) versus SGA-A (well-nourished) groups indicating 







Chapter 5  
5 Fat-free mass index controlled for age and sex, and 
malnutrition are predictors of survival in interstitial lung 
disease. 
 Abstract 
Background: Literature focusing on nutritional variables and survival in interstitial lung 
disease (ILD) is limited by its focus on weight and body mass index (BMI) and has not 
considered body composition. Objectives: The primary objective of this study was to 
examine whether body composition measures, specifically fat-free mass index z-score (z-
FFMI) and body fat mass index z-score (z-BFMI), were predictors of survival in ILD 
patients. The second objective was to examine if nutrition status was a predictor of survival. 
Method: 78 outpatients diagnosed with fibrotic ILD were recruited in this cross-sectional 
study. Body composition data using dual frequency bioelectrical impedance analysis 
(BodyStat 1500MD, UK), and nutrition status was determined using the subjective global 
assessment (SGA). To control for age and sex, z-FFMI and z-BFMI were calculated using 
population means. Participant charts were reviewed for diagnosis age, disease severity and 
exercise capacity. Results: Age [HR 1.08, 95% CI (1.03-1.13), p<0.01], BMI [HR 0.90, 
95% CI (0.84-0.97), p<0.01)], z-FFMI [HR 0.70, 95% CI (0.56-0.87), p=0.02], z-BFMI 
[HR 0.74, 95% CI (0.57-0.96), p<0.01], six-minute walk distance (6MWD) [HR 0.99, 95% 
CI (0.99-1.00), p<0.01], % predicted diffusing capacity for carbon monoxide (%DLco) 
[HR 0.93, 95% CI (0.89-0.97), p<0.01] and severe malnutrition (SGA-C) [HR 6.98, 95% 
CI (2.00-24.27), p<0.01] were significant predictors of survival. When controlled for 
exercise capacity and disease severity, z-FFMI and severe malnutrition were significant 
predictors of survival independent of %DLco. Conclusion: z-FFMI and severe malnutrition 








Interstitial lung disease (ILD) is a group of disorders that involve disruption of the distal 
lung parenchyma, with various degrees of inflammation and/or fibrosis. A common form 
of ILD is idiopathic pulmonary fibrosis (IPF) and is characterized by progressive scaring 
of the lung parenchyma, with minimal inflammation. IPF is relentlessly progressive, with 
a dismal prognosis of 2-5 years, in the absence of treatment (Raghu et al. 2011). Clinical 
markers such as lung function, 6-minute walk distance (6MWD), dyspnea scores and 
body mass index (BMI) are reliable predictors of survival in ILD (Alakhras et al. 2007; 
Collard et al. 2003; Manali et al. 2008). To date, research examining the relationship 
between nutritional factors and survival in ILD is limited by its focus on weight and BMI 
and has not fully addressed the influence of body composition and overall nutrition status 
on survival.  
Low fat-free mass index (FFMI), fat-free mass standardized for height, has been shown to 
be a predictor of mortality in various disease states (Chang et al. 2019; Schols et al. 2005). 
In IPF, Nishiyama et al. (2017) found that FFMI, but not BMI, was a significant predictor 
of survival. Age, sex and height are core biological factors affecting fat-free mass, but it 
may also be affected by environmental factors such as physical activity and protein intake. 
Therefore, the calculation of a FFMI z-score (z-FFMI) aims to account for some of these 
confounding factors by generating a value indicating how far away an individual’s measure 
is from the mean of healthy population reference values. Similarly, this can be used to 
calculate body fat mass index z-scores (z-BFMI).  
In other chronic lung diseases, a significant portion of patients have been identified as 
malnourished (Günay et al. 2013; Gupta, Kant, and Mishra 2010). In ILD, the prevalence 
of malnutrition is not well established. The gold standard of nutrition assessment is the 
subjective global assessment (SGA) which has been validated in a variety of disease states 
(Baccaro et al. 2007; Detsky et al. 1987). SGA considers diet, weight history, functional 
status, gastrointestinal issues, and disease history, combined with a physical examination 
to identify signs of muscle wasting, subcutaneous fat loss, and edema, taken together to 





The primary objective of this study was to examine whether measures of body composition, 
specifically z-FFMI and z-BFMI, are independent predictors of survival in ILD patients. 
The second objective was to determine the prevalence of malnutrition using SGA and 
examine if nutrition status is a predictor of survival. 
 Methods 
5.3.1 Study Population 
In this cross-sectional study, 78 patients diagnosed with fibrotic ILD were recruited from 
an outpatient ILD clinic. Inclusion criteria included ambulatory patients over 18 years of 
age with diagnosis of a fibrotic ILD. Patients were excluded according to the following 
criteria: inability to provide consent due to communication issues (cognitive and motor), 
presence of cardiac implantable electrical devices, non-stable ILD patients defined as those 
with infections and/or fever, admitted to hospital in the previous month, or presence of an 
unstable co-morbid illness. The study protocol was approved by the Western University 
Research Ethics Board (protocol n. 104028 and 103186).  
5.3.2 Diagnosis, Disease Severity and 6-Minute Walk Test 
The presence of fibrotic ILD was defined based on high-resolution chest computed 
tomography scan and compatible pulmonary function tests. After excluding all known 
causes of ILD, IPF was diagnosed based on clinical and radiographic criteria, and when 
necessary, on surgical lung biopsies, followed by multi-disciplinary discussion (Flaherty 
et al. 2004; Raghu et al. 2018). The diagnosis of fibrotic ILD other than IPF was based on 
clinical presentation, laboratoristic, bronchoscopic, radiographic investigations, and when 
indicated (e.g. non-specific interstitial pneumonia cases), surgical lung biopsies. Patients 
with combined pulmonary fibrosis and emphysema (CPFE) were also excluded from the 
study, and coexisting emphysema was always minimal (≤5% of total lung volume). Patient 
charts were also reviewed for current medications and results of pulmonary function tests 
and six-minute walk tests. Pulmonary function tests and six-minute walk tests were 
performed as part of patients’ standard of care and according to the American Thoracic 





Spirometry, 1994 Update. American Thoracic Society. 1995). Time from diagnosis was 
calculated from date ILD was diagnosed to study recruitment date. 
5.3.3 Body Composition Assessment  
Body composition data were obtained using dual frequency bioelectrical impedance 
analysis (BIA) (BodyStat 1500MD, UK). BIA is an easy and convenient bedside tool that 
is validated in a variety of clinical settings (Fuller, Sawyer, and Elia 1994; Ghosh et al. 
1997; Steiner et al. 2002). Participants were asked to rest supine on a bed in the clinic while 
breathing normally. Resistance and reactance were measured via passing a 50 kHz 
electrical current through the body via two electrodes placed on the surfaces of the right 
hand and foot while measuring the impedance at fixed frequencies (BodyStat 2017). FFMI 
and BFMI were calculated using estimates of fat-free mass and body fat mass obtained 
using BIA according to the following equations: FFMI= fat-free mass (kg) / [height (m)]2, 
and BFMI= body fat mass (kg) / [height (m)]2, respectively. z-FFMI and z-BFMI were then 
calculated using population means by age and sex groups (Kyle et al. 2001) according to 
the following equation: z-score = (x - xpopulation mean)/ standard deviationpopulation (SD). FFMI 
and BFMI cut-offs suggested by Kyle et al. (2001) were used to classify patients into the 
following categories: normal (normal FFMI and BFMI), sarcopenia (low FFMI and normal 
BFMI), obesity (normal FFMI and high BFMI), and sarcopenic obesity (low FFMI and 
high BFMI) (Kyle et al. 2005). 
5.3.4 Nutrition Assessment  
SGA was completed according to the method outlined by Detsky et al (1987) and was 
completed by a registered dietitian (SR). SGA is considered the gold standard method to 
identify malnutrition combining dietary, weight, functional, gastrointestinal and disease 
history with a physical examination to arrive at a categorical ranking. Categories A, B 
and C represent well-nourished, moderate malnutrition or suspected of being 






The primary outcome measure was 2-year lung transplant-free survival. The survival of 
patients was assessed starting from the time of their BIA assessment up to 2 years following 
this date.  
5.3.6 Statistical Analysis  
Descriptive statistics were evaluated; continuous variables are expressed as mean ± 
standard deviation (SD) and categorical variables are displayed as frequencies. An 
independent samples t-test was used to compare differences in means between sexes. Cox 
proportional hazard regression models were performed to identify significant predictors of 
survival. Receiver operator characteristic (ROC) analyses were used to determine the best 
cut point of a variable towards the endpoint, by examining accuracy of predicting endpoints 
(sum of sensitivity and specificity). Lung transplant-free survival was evaluated using 
Kaplan-Meier curves and the log rank test. P-values <0.05 were regarded as significant. 
Statistical analysis was performed with IBM® SPSS® Statistics Version 26 software 
package. 
 Results 
Patient characteristics including diagnosis, clinical characteristics, body composition and 
nutrition status are shown in Table 10. Mean age was 68.4±10.0 years. 51.3% of 
participants were female. Mean BMI was 30.8±7.3 kg/m2. As expected, FFMI was 
significantly greater in males versus females (p<0.001), and BFMI was significantly lower 
in males versus females (p<0.001). Mean z-FFMI and z-BFMI, standardized for age and 
sex population norms (Kyle et al. 2001), were 0.39±1.98 SD and 2.27±2.15 SD, 
respectively. Most patients were diagnosed with moderate malnutrition (49%). 60.3% of 
participants were classified as obese, while 11.5% had a normal body composition, 20.5% 
had sarcopenia and 7.7% were sarcopenic obese. Mean observation time was 19.4±7.3 
months. At the end of the 2-year observation period, 26% (n=20) of participants had passed 






Table 10 Patient demographics (N=78). 
Clinical Characteristics 
Mean ± SD  
or Frequency (%) 
Age (years) 68.4 ± 10.0 
Sex   
   Male 38 (48.7) 
   Female 
 
40 (51.3) 
Diagnosis   
Idiopathic pulmonary fibrosis 36 (46.2) 
Drug-induced toxicity 10 (12.8) 
Rheumatoid arthritis related ILD 8 (10.3) 
Non-specific interstitial pneumonia 8 (10.3) 
Chronic hypersensitivity pneumonitis 5 (6.4) 
Unclassifiable ILD  4 (5.1) 
Scleroderma-related ILD 3 (3.8) 
Vasculitis-related ILD 2 (2.6) 
Sarcoidosis (stages III-IV) 2 (2.6) 
  
Years from diagnosis [median (range)] 1 (0-13)  
ILD Medications  
Proton pump inhibitors 43 (55.1) 
Oxygen supplementation 24 (30.8) 
Pirfenidone 16 (20.5) 
N-acetylcysteine 12 (15.4) 
Nintedanib 2 (2.6) 
  
Anthropometry and Nutritional Indices 
BMI (kg/m2) 30.8 ± 7.3 
FFMI (kg/m2) 18.2 ± 3.6* 
   male 20.0 ± 3.6 
   female 16.4 ± 2.7 
BFMI (kg/m2) 12.6 ± 5.5* 
   male 9.9 ± 3.8 
   female 15.2 ± 5.7 
  FFMI z-score (SD) 0.39 ± 1.98 
  BFMI z-score (SD) 2.27 ± 2.15 
  
Body Composition   
Normal 9 (11.5) 
Sarcopenia 16 (20.5) 
Obesity 47 (60.3) 
Sarcopenic Obesity 6 (7.7) 
   


























       SGA-A (well-nourished) 34 (43.6) 
       SGA-B (moderate malnutrition) 38 (48.7) 
    SGA-C (severe malnutrition)  6 (7.7) 
  
Pulmonary Function and Exercise Capacity 
FEV1 (% predicted) 75.1 ± 18.9 
FVC (% predicted) 71.1 ± 19.5 
DLCO (% predicted) 40.6 ± 17.1 
6MWD (m) 335.6 ± 109.8 
6MWD (% predicted) 74.4 ± 22.9 
Continuous variables are expressed as mean ± standard 
deviation. BFMI, body-fat mass index; BMI, body mass 
index;  FFMI, fat-free mass index; IPF, idiopathic 
pulmonary fibrosis; ILD, interstitial lung disease; SD, 
standard deviation; SGA, subjective global assessment; 
6MWD, six-minute walk distance; %DLCO, percent 
predicted diffusing capacity for carbon monoxide; %FEV, 
percent predicted forced expiratory volume; %FVC, 
percent predicted forced vital capacity. 
* independent samples t-test indicated significant 





The results of the univariate Cox proportional hazard model are summarized in Table 11. 
Age was not included in the models as z-FFMI, z-BFMI and %DLco values control for 
differences in age. z-FFMI and SGA were not included in the same model as a component 
of SGA includes assessment of loss of fat-free mass. The results of the multiple Cox 
proportional hazard models are shown in Table 12. z-FFMI was a significant predictor of 
survival independent of z-BFMI and %DLco but not 6MWD (Models 1-3, Table 12). 
SGA-C (severe malnutrition) as compared to SGA-A (well-nourished) was a significant 







Table 11 Univariate Cox proportional analysis. 
Variable HR 95% CI p-value 
Sex 1.76 (0.72-4.32) 0.22 
Age 1.08 (1.03-1.13) <0.01 
Time from diagnosis 1.00 (0.85-1.17) 0.96 
    
Prednisone 0.75 (0.29-1.95) 0.56 
Pirfenidone 1.91 (0.73-4.98) 0.19 
N-acetylcysteine  3.17 (1.21-8.28) 0.02 
Supplemental oxygen  1.76 (0.72-4.31) 0.22 
MMF 0.04 (0.00-10.03) 0.25 
    
%FEV1  0.99 (0.97-1.02) 0.51 
%FVC  0.99 (0.97-1.01) 0.36 
%DLCO
  0.93 (0.89-0.97) <0.01 
    
BMI 0.90 (0.84-0.97) <0.01 
z-FFMI 0.70 (0.56-0.87) <0.01 
z-BFMI 0.74 (0.57-0.96) 0.02 
6MWD 0.99 (0.99-1.00) <0.01 
    
SGA-A (well-nourished) 1 --- --- 
SGA-B (moderate malnutrition) 2.04 (0.70-5.96) 0.20 
SGA-C (severe malnutrition)  6.98 (2.00-24.27) <0.01 
    
Normal 1 ---- --- 
Sarcopenia 5.49 (0.69-43.97) 0.11 
Obesity 1.66 (0.21-13.28) 0.63 
Sarcopenic Obesity 5.61 (0.58-54.06) 0.14 
    
Obesity 1 ---- --- 
Sarcopenic Obesity 3.23 (0.85-12.21) 0.08 
BMI, body mass index; CI, confidence interval; HR, hazard ratio; SGA, subjective 
global assessment; z-BFMI, body-fat mass index z-score; z-FFMI, fat-free mass 
index z-score; 6MWD, six-minute walk distance; %DLCO, percent predicted 
diffusing capacity for carbon monoxide; %FEV1, percent predicted forced 








Table 12 Cox regression analyses to identify independent predictors of lung transplant-
free survival. 
Variables HR 95% CI p-value 
Model 1    
z-FFMI (SD) 0.72 (0.53-0.98) 0.03 
z-BFMI (SD) 0.78 (0.69-1.32) 0.78 
    
Model 2    
z-FFMI (SD) 0.67 (0.51-0.86) <0.01 
%DLCO  0.92 (0.88-0.97) <0.01 
    
Model 3    
z-FFMI (SD) 0.82 (0.65-1.03) 0.09 
6MWD (m) 0.99 (0.99-1.00) <0.01 
    
Model 4    
SGA-A (well-nourished) 1 ------ ----- 
SGA-B (moderate malnutrition) 2.06 (0.56-7.63) 0.28 
SGA-C (severe malnutrition) 7.24 (1.68-31.15) <0.01 
%DLco  0.93 (0.89-0.97) <0.01 
    
Model 5    
SGA-A (well-nourished) 1 ---- ---- 
SGA-B (moderate malnutrition) 1.42 (0.47-4.26) 0.54 
SGA-C (severe malnutrition) 3.13 (0.75-13.01) 0.12 
6MWD (m) 0.99 (0.99-1.00) <0.01 
CI, confidence interval; HR, hazard ratio; SD, standard deviation; SGA, 
subjective global assessment; z-FFMI, fat-free mass index z-score; z-BFMI, 
body-fat mass index z-score; 6MWD, six-minute walk distance; %DLCO, 
percent predicted diffusing capacity for carbon monoxide. 
 
Results of ROC analysis for z-FFMI is displayed in Table 13. The ideal z-FFMI cut-off 
was <0.37 SD with 62.1% sensitivity and 80.0% specificity. Kaplan-Meier survival curves 







Table 13 Results of receiver operator characteristic analysis 
 





z-FFMI 0.74 (0.62-0.87) <0.01 0.37 62.1 80.0 
AUC, area under the curve; CI, confidence interval; SD, standard deviation; z-
FFMI, fat-free mass index z-score.  
 
 
Figure 4 Kaplan–Meier survival curve using ideal cut-off for fat-free mass index z-score 
(z-FFMI) (p=0.001). The solid line represents z-FFMI ≥ 0.37 SD and the dotted line 
represents z-FFMI <0.37 SD. Survival curves was compared using log-rank statistics  









This study examined the influence of body composition parameters, z-FFMI and z-BFMI, 
and nutrition status on survival in a group of fibrotic ILD patients. z-FFMI, z-BFMI and 
severe malnutrition (SGA-C) were shown to be significant predictors of survival in ILD. 
However, when controlled for disease severity only z-FFMI and severe malnutrition were 
independent predictors of survival in ILD patients.  
In our univariate analysis BMI was found to be a significant predictor of survival in ILD 
patients. Research focusing on BMI and survival in IPF patients has demonstrated a 
paradoxical effect of obesity on survival, in that, an increased BMI acts as a protective 
factor on mortality. In a study by Alakhras et al. (2007), individuals with BMIs in the obese 
category (>30kg/m2) were shown to have significantly greater survival times than those 
with BMIs in the overweight category (25-30kg/m2) and normal category (<25kg/m2). 
Similarly, Mura et al. (2012) reported that for every 1-unit increase in BMI there was a 
11% lower risk of death at 3-year follow-up in IPF patients (HR 0.89, 95% CI (0.80–0.98), 
p=0.0165). Adding to these results, progressive weight loss greater than 5% of total body 
weight in 1 year has also been found to be an independent predictor of decreased survival 
in IPF (Nakatsuka et al. 2018). Limited studies exist showing the relationship between 
increased BMI and decreased mortality in ILDs other than IPF. One recent study, which 
included a diverse group of ILDs including ILD secondary to connective tissue disease, 
hypersensitivity pneumonitis, and unclassifiable subtypes found that a loss in BMI greater 
than 5% in 1 year was associated with significantly shorter survival times, and there was a 
2-fold higher risk of death compared to those with a ≤5% loss in BMI in 1 year (Pugashetti 
et al. 2018). These results suggest that excess weight may act as a nutritional reserve in 
times of poor intake secondary to harsh side effects of medications, or during acute 
exacerbations of the disease. Interestingly, we found that only use of N-acetylcholine, an 
ILD medication used for its antioxidant effect (Sun, Liu, and Zhao 2016), was associated 
with worsened mortality, but corticosteroids, and other anti-fibrotic and anti-inflammatory 






A strong relationship exists between decreased FFMI and poor prognosis in other chronic 
respiratory diseases such as chronic obstructive pulmonary disease (Gologanu et al. 2014; 
Schols et al. 2005; Vestbo et al. 2006); however, fewer studies exist in ILD. We 
demonstrated a 30% reduction in risk of death for every 1 SD increase in z-FFMI in our 
sample of 78 fibrotic ILD patients. Two recent studies exist examining FFMI and survival 
in IPF patients. The first study by Nishiyama et al. (2017) found a 36% lower risk of death 
with every 1-unit increase in FFMI (HR 0.64, 95% CI (0.43–0.94), p=0.02) in a group of 
Japanese IPF patients. Conversely, in a study of IPF patients by Patel et al. (2018) there 
was no significant association between FFMI and all-cause mortality at 1-year. Although 
conflicting results, neither study controlled for age or sex when analyzing FFMI. Notably, 
despite not controlling for confounding factors, Nishiyama et al. (2017) did demonstrate 
FFMI to be a significant predictor of survival in their study. This could be due to a non-
significant difference in FFMI in males versus females in this sample. Different body 
composition norms in Japanese versus Caucasian cohorts such as lower BMI and FFMI 
have been demonstrated in previous studies (Jensen et al. 2019).  However, between sex 
statistics were not reported. Patel et al. (2018) did not adjust for sex differences in their 
univariate analysis using FFMI as a continuous variable, however, when FFMI was used 
as a categorical variable, sex specific cut-offs were applied (FFMI ≥15 kg/m2 for females 
and ≥17 kg/m2 for males). A reference source for these cut-offs was not indicated, however, 
it is assumed that these cut-offs are based on the European Society for Parenteral and 
Enteral Nutrition diagnostic criteria for malnutrition (Cederholm et al. 2015). Although an 
important contributor to survival, cuts-offs derived for identification of malnutrition may 
not be sensitive or specific to predicting survival outcomes, thus, influencing these non-
significant findings. Our study intended to control for patient characteristics such as age 
and sex which influence FFMI. Using z-FFMI we were able to include both males and 
females together in our analyses, and we were able to control for factors such as age-related 
fat-free mass loss which can skew results.  
We also addressed the impact of body fat on survival. Interestingly, we found that z-BFMI 
was a significant predictor of survival. Although it has been demonstrated that excess 
weight can increase the workload of breathing and decrease physical performance (Tynan 





protective on survival. It is very likely that the protective effect of excess body fat on 
survival observed in this study is related to the relationship between fat-free mass and body 
fat mass, in that, as body fat mass increases, greater amounts of fat-free mass may be 
required to support this excess weight. Therefore, FFMI may be maintained through a 
weight bearing effect. This is further supported by results of our analysis, in which z-BFMI 
was no longer a significant predictor of survival when controlled for z-FFMI. These results 
appear to suggest a component of sarcopenic obesity affecting the significance of z-BFMI 
as a predictor of survival in the presence of worsened disease status and poor exercise 
capacity. Specifically, research has shown that excess body fat mass, especially in the 
presence of fat-free mass, can have direct detrimental effects on physical performance 
(Joppa et al. 2016), systemic inflammation (Joppa et al. 2016), quality of life (Joppa et al. 
2016; Öztürk et al. 2018) and prognosis (Gonzalez et al. 2014). We attempted to determine 
the influence of body composition on survival, however, we found no significant difference 
in odds of death in those with sarcopenia, obesity, nor sarcopenic obesity versus those with 
a normal body composition. Additionally, we assessed the specific difference between the 
obese and sarcopenic obese groups, however, there was no significant difference (p=0.085) 
in chance of death in sarcopenic obesity versus obesity. However, with only 6 patients 
identified as sarcopenic obese, our statistical power was limited.  
Prevalence of malnutrition in ILD patients has been understudied, and clinical practice 
guidelines for the treatment and management of ILD offer limited guidance related to 
nutrition (Raghu et al. 2011, 2018). Of the existing research, malnutrition prevalence varies 
greatly, and is often identified by a single measure. Jouneau et al. (2019) found that 28% 
of patients were malnourished using fat-free mass, 4% were malnourished using BMI, and 
5% were malnourished using mid-arm circumference. A conference abstract by Autore et 
al. (2013) reported that 26% of patients were at risk of malnutrition using the Mini 
Nutritional Assessment Short Form, a validated screening tool designed for populations 
>65 years. In our study, the majority of patients were diagnosed with malnutrition, and 
those with severe malnutrition, had a 7-fold increased risk of death compared to well-
nourished patients. To the best of our knowledge, this study is the first to use a 





The modest sample size was a limiting factor of this study. First, we were limited to 
including no more than two predictor variables in the multiple Cox regression models 
keeping in line with the general recommendation that for every one predictor variable 
n=10 outcomes, in this case deaths, are required to reduce the risk of overfitting the 
model (Norman 2013). Therefore, we were not able to control for both disease severity 
and exercise capacity with body composition parameters and nutrition status in the same 
model which may have produced different results. Second, with only 6 participants 
identified as sarcopenic obese we were not able to fully address the question of whether 
increased body fat is protective in all cases. Similarly, limited numbers in our severe 
malnutrition group limited statistical power in our analyses. Our cross-sectional study 
only assessed body composition, disease severity and exercise capacity at one time point, 
however, monitoring changes over time, such as change in body composition or change 
in %FVC, can provide additional insights into their influences on survival. Additionally, 
we did not use a cohort of healthy individuals for comparison with our sample. However, 
the nature of calculating z-scores of body composition parameters innately compares our 
sample to healthy population norms of FFMI and BFMI. Lastly, it would be remiss to not 
acknowledge that BIA provides estimations of body composition using prediction 
equations. Therefore, our results are limited due to the use of estimates of fat-free mass 
and body fat mass rather than actual measurements. However, our results are in-line with 
previous research that has shown that adiposity (Alakhras et al. 2007) and low muscle 
mass (Mendes et al. 2015) is common in ILD.  
 Conclusion 
These results are sufficiently encouraging to warrant further research into the nutritional 
status of ILD patients. Future research should focus on the influence of sarcopenic 
obesity on survival, and how nutrition interventions targeted at maintaining or increasing 
muscle mass over time can affect survival in ILD patients. Furthermore, assessment of 
fat-free mass should be considered alongside or in place of BMI as a nutritional variable 
when analyzing survival risk of ILD patients as it can better identify those as risk of 
death. Additionally, chest computed tomography scans which are completed as part of 





composition parameters using a gold standard method. In conclusion, in our sample of 78 
fibrotic ILD patients, z-FFMI and severe malnutrition independent of disease severity 







6 Overall Conclusion and Future Directions 
The overarching purpose of this dissertation research was to better understand the 
nutritional concerns in interstitial lung disease (ILD) patients through investigating the 
contributions of body composition and nutrition status on exercise capacity and survival 
in patients with ILD. This final chapter will discuss the contributions to research, clinical 
implications and recommendations, the challenges and limitations of this thesis research, 
future research plans, and end with an overall conclusion.  
 Research Contributions 
This dissertation makes several key contributions to knowledge. Chapter 2 reviewed the 
literature on ILD background and nutrition-related knowledge to date in ILD. The key 
finding from this literature review was that there are numerous nutrition-related concerns 
associated with ILD and its treatment which put patients at nutritional risk. Despite this, 
nutrition professionals such as registered dietitians (RDs) may not be part of the standard 
ILD health care team. This overlooks an important opportunity to improve quality of life 
and survival through supporting patients’ nutritional needs.  
Chapter 3 examined the appropriateness of phase angle (PhA) as a nutrition indictor in 
various disease states. This study was the first systematic review comparing the 
subjective global assessment (SGA) which is the gold standard of nutrition assessment 
with bioimpedance PhA. The key finding of this systematic review was that overall 
evidence quality received a grade of Low, and that continued research is needed in this 
area to validate surrogate markers of nutrition status in a variety of disease states.  
The objective of Chapter 4 was to examine the relationship between nutrition status and 
body composition with functional exercise capacity, and to determine the appropriateness 
of bioimpedance parameters (PhA and impedance ratio (IR)) to identify malnutrition in 
ILD patients. The results of Chapter 4 showed that SGA-C (severe malnutrition) and low 
fat-free mass index z-score (z-FFMI) were associated with worsened exercise capacity in 





was associated with severe malnutrition. A research gaps exists in the areas of body 
composition, nutrition status and surrogate markers of nutrition in ILD. The results of this 
chapter address these research gaps. These finding are important to the body of research 
on nutrition status and body composition in ILD as it demonstrates that malnutrition or 
loss of fat-free mass can negatively impact a person’s ability to perform their activities of 
daily living and therefore affect their quality of life.  
The purpose of Chapter 5 was to evaluate body composition measures and nutrition 
status as predictors of survival in ILD. The results of Chapter 5 revealed that z-FFMI 
and SGA-C (severe malnutrition) are independent predictors of survival in patients with 
ILD. The findings in this chapter are important to the research field as it challenges 
previous research that has narrowly focused on increased weight as a protective factor in 
the survival of ILD patients. Rather, this research indicates that increased fat-free mass is 
an important component of body weight which offers a protective effect on survival in 
ILD. Also, this research is the first to assess the relationship between nutrition status and 
survival. The key finding that severe malnutrition, but not moderate malnutrition, was 
associated with decreased survival in ILD adds to the ILD knowledge base and warrants 
further research exploration.  
 Clinical Implications  
This research provides justification for the need of nutrition professionals as part of a 
holistic approach in the care of ILD patients. Previous research has identified patient 
education, symptom relief and management of comorbidities as vital components of 
supportive care in ILD management (Quinn, Wisse, and Manns 2019). RDs can support 
patients in each of these three supportive care components using their nutrition expertise 
and skills.  
ILD medications are commonly associated with adverse events such as decreased 
appetite, nausea or diarrhea, which put patients at nutritional risk. For example, diarrhea 
is a common adverse event of the medication Nintedanib (OFEV®), and many patients 
may discontinue its use due to this side effect (Galli et al. 2017). Specific nutrition 





bowel frequency as well as prevent additional complications such as dehydration and 
malabsorption. Additionally, RDs can support patients to correct or prevent malnutrition. 
For example, decreased intake and/or increased energy requirements related to the 
increased work of breathing can result in loss of fat-free mass and malnutrition.  
RDs can address and educate patients on the conflicting weight-related research in ILD. 
For instance, as thoroughly discussed in Chapter 2, an increased body mass index (BMI) 
is associated with decreased mortality in ILD patients (Alakhras et al. 2007; Mura et al. 
2012), however, this conflicts with both general health weight recommendations and 
BMI cut-offs required for lung transplantation. Dietetics is an evidenced-based 
profession; therefore, RDs can address nutrition misconceptions and misunderstandings 
and provide credible, evidence-based information to ILD patients. RDs can help patients 
establish and maintain their own individualized weight and body composition targets. 
RDs are qualified to identify indictors of muscle or body fat loss and therefore assess for 
risk of sarcopenia and sarcopenic obesity. Therefore, RDs should be included in standard 
ILD care in order to establish targetable nutrition care plans for common nutrition 
problems thereby improving symptom management and quality of life.  
 Reflections on Research Challenges 
Although the research process can provide a great deal of gratification it also can bring 
about challenges. A main difficulty I encountered with this dissertation research was 
related to recruitment and timing. Participant recruitment in a relatively rare and 
specialized disease can be difficult. In my case, I was fortunate to be working in the ILD 
clinic serving southwestern Ontario. However, this meant that patients were frequently 
travelling from out of town for their clinic visit with their respirologist, and for some, this 
also meant that they were not willing to stay the extra time required for the data 
collection required for this study. Furthermore, being a specialized clinic, it only occurred 
on one half day per week. Therefore, there were only a limited number of participants 
available to recruit each week.  
A large challenge was our recruitment capacity at each clinic, specifically related to 





(BIA) device (BodyStat® 1500MDD) for data collection and having only one RD 
available to complete the SGA. For example, if all scheduled clinic patients were to 
consent to this research study, our capacity as a research team (myself, the RD required 
for specific data collection and a variable number of student volunteers each week) would 
only be able to collect data on 4-5 participants per clinic at a maximum. As well, patient 
clinic visits were generally scheduled 4-6 months apart which meant that if a patient was 
interested in participating in the research study, but was not able to be seen on that day 
due to time restraints, the research team would possibly have to wait another 4-6 months 
to see that patient again. Lastly, with respect to our survival research, our study timeline 
was lengthened to allow for a 2-year survival time. Therefore, in preparation for this 
dissertation research we were required to limit our cohort to N=78 participants in order to 
have the necessary survival data for our analyses.  
 Limitations 
The main limitation of this research was sample size. Our sample size of n=78 in both 
studies limited our ability to assess the influence of specific diagnoses, medication use 
and body composition categories, such as sarcopenic obesity, in our analyses. 
Specifically, we have limited statistical power to assess the influence of sarcopenic 
obesity (n=6) on survival. As a result, we were not able to fully address the question of 
whether increased body fat mass was protective in all cases. Similarly, although we 
reported significance in our analyses of the SGA-C (severe malnutrition) group in its 
association with exercise capacity and survival, SGA-C (severe malnutrition) was no 
longer a significant predictor of survival when controlled for exercise capacity. As well, 
we found no significant difference in SPhA across SGA groups. Therefore, without 
greater sample size, we could not say with certainty if there is truly no relationship or if 
these non-significant results were due to limited statistical power.  
In our survival analyses in Chapter 5, we were limited to including no more than two 
predictor variables in the multiple Cox regression models keeping in line with the general 
recommendation that n=10 outcomes, in this case deaths, are required for every one 
predictor variable to reduce the risk of overfitting the model (Norman 2013). Therefore, 





composition parameters and nutrition status within the same model which may have 
produced different results.  
Another limitation of this study is that it is cross-sectional in nature and only assessed 
body composition, lung function and exercise capacity at only one time-point; however, 
monitoring changes over time, such as change in body composition or change in percent 
forced vital capacity (%FVC) would provide more valuable insights into their influences 
on survival and exercise capacity. Additionally, we acknowledge that ILD patients are a 
heterogeneous group, however, our study population included only fibrotic-ILDs which 
aimed to limit diagnosis-specific differences among our participants. Furthermore, we did 
not use a cohort of healthy individuals for comparison with our sample. However, the 
nature of calculating z-scores innately compares our sample to healthy population norms 
of FFMI, body-fat mass index (BFMI), PhA and IR. Lastly, it would be remiss to not 
acknowledge that BIA provides estimations of body composition using prediction 
equations as discussed in Chapter 2 Section 2.2.2.1.3; therefore, our results are limited 
due to the use of estimates of fat-free mass and body-fat mass rather than actual 
measurements. However, in a clinical setting, BIA is the most cost-efficient and practical 
application. Although, this research was limited by sample size and, therefore, we could 
not preform subgroup statistical analyses, there is reason to believe that individuals with 
ILD would benefit from nutrition intervention and support.  
 Future Research Recommendations and Plans 
Continued research is needed to better understand the complex needs of patients with 
ILD. There are many research areas that can be further explored within the ILD 
population; however, we have identified the most notable research gaps warranting 
further exploration. Continued nutrition-related research is needed to increase study 
samples size in order to thoroughly explore the risk of malnutrition with specific 
medication use and between ILD subtypes, as well as to further explore the influence of 
sarcopenic obesity on survival. This may be achieved by a multi-site research study.   
There is a notable gap in the research regarding nutrition interventions in ILD, despite 





guidelines. First, monitoring of nutrition status and body composition longitudinally is 
needed to better understand how they relate to clinical parameters such as lung function, 
exercise capacity, and survival. Second, research should explore the impact of nutrition 
interventions, for example, to improve or preserve muscle mass and explore its relation to 
survival, exercise capacity and/or quality of life of patients with ILD. Lastly, within these 
future directions, there is great possibility for interprofessional collaboration. For 
example, collaboration with physiotherapists would be important to examine the potential 
synergistic effect between nutrition interventions and physiotherapy as part of pulmonary 
rehabilitation aimed at increasing muscle mass and exercise capacity, and thus improving 
patient outcomes.  
This research was part of a larger overall study which collected dietary intake 
information, biochemical data such as calcium and vitamin D serum levels and functional 
data such as hand-grip strength. Data analysis is planned to assess adequacy of intake in 
our sample population. This will allow for exploration into the relationship between 
protein intake and body composition, and vitamin D intake and serum blood levels in 
ILD patients. As well, the relationship between hand-grip strength, a quick and easy 
measure of functional capacity, and nutrition status and body composition will be 
explored. The results of this planned research may help lay the foundation for further 
interventional research.   
As this research was limited by its use of bioelectrical impedance analysis to determine 
estimated, rather than measured, body composition parameters, we are currently 
completing a research study on the use of chest computed topography (CT) scans to 
measure body composition parameters using a gold standard method. This research 
project aims to determine the prevalence of sarcopenia, or low muscle mass, and 
sarcopenic obesity using computed tomography scans in ILD patients both at diagnosis 
and through disease progression and which will be used to assess for survival risk. As 
well, fat-free mass and body fat mass measured using computed tomography imaging, in 
select cases, will be correlated with predictions of body composition assessed using BIA 
in order to determine ILD-specific derived BIA regression equations. See Appendix E 






In conclusion, in our sample of 78 fibrotic ILD patients, decreased z-FFMI which was 
controlled for age and sex, and SGA-C (severe malnutrition) were significantly 
associated with exercise capacity in fibrotic ILD patients independent of lung function. 
SPhA was not significantly different between SGA groups, however, z-IR, which 
measures cell health, was significantly greater in the SGA-C (severe malnutrition) versus 
SGA-A (well-nourished) group indicating worsened cell health in severe malnutrition. z-
FFMI and severe malnutrition independent of disease severity were significant predictors 
of survival in ILD patients. Continued research should focus on nutrition assessment, 
intervention and monitoring as this will result in improved understanding of the complex 
nutritional concerns of ILD patients. Better understanding these complex needs and 
involving nutrition professionals such as RDs in the standard care of ILD patients can 
help ensure that ILD patients are provided with the appropriate supports to best manage 
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NUTRITIONAL STATUS OF PATIENTS WITH INTERSTITIAL LUNG 
DISEASE: A CROSS SECTIONAL STUDY 
 
LETTER OF INFORMATION 
 
Introduction 
My name is Dr. Janet Madill and I am a Professor in the Foods and Nutrition Department at 
Brescia University College.  I am currently conducting research into the nutritional status of 
patients with interstitial lung disease and would like to invite you to participate in this 
study.  I am working with Dr. Marco Mura, your respirologist.  The purpose of this 
information letter is to provide you with enough information for you to decide if you would 
like to participate in the study.   
 
Purpose of the study 
The purpose of this study is to assess the nutritional status of patients with interstitial lung 
disease (ILD), as there is currently little to no information available for patients with ILD. 
ILD is a disease process whereby the lungs become inflamed and scarred. The aim of the 
study is to measure body composition and nutritional status as this relates to disease and 
to determine the appropriate nutrition care plan for patients with interstitial lung disease.  
If you agree to participate 
If you agree to participate in this study, during your clinic visit, we will review with you 
what you have eaten in the last 24-hours. We will provide you with a 3-day food record 
sheet, for you to take home and explain to you how to fill in the sheets. We will also ask you 
if you would prefer, we call you at the end of each of the 3-days to record what you have 
eating, or you may fill in the 3-day food record on your own. As well, we will record your 
height and weight. Your body composition, or the amount of muscle, fat and fluid in your 
body, will be measured using a BodyStat Analyzer. This will involve resting comfortably on 
a bed in the clinic and breathing normally. We will attach 2 electrodes each to the surface of 
your foot and hand and record for 2-3 minutes. The BodyStat Analyzer is a non-invasive 
device, which measures the impedance value of the body providing quick and effective 
analysis of body composition. This is a painless process and it works by passing a safe 
battery generated signal through the body and measuring the impedance at a fixed 
frequency. We will measure the thickness of your quadriceps femoris muscle in your thigh 
using a portable ultrasound machine. This will require you to lay flat on a clinic bed during 
the measurement and will require you to expose the skin of your mid though so we can 
access to the skin surface. Ultrasound gel and probe will be placed directly on skin surface 
using light pressure to produce an ultrasound image used to measure the thickness of your 
muscle. Lastly, we will measure your hand-grip strength. This will require you to sit upright 
in a chair, and using each hand, squeeze a dynamometer machine as hard as you can. This 
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will be repeated three times for accuracy. All testing will be completed during your normal 
clinic visit and no additional visits will be required. You may need to stay an additional 
thirty to sixty minutes to complete this study. In some cases, if you are not able to make it 
to clinic, you may be approached for a visit to take place in the community where members 
of the study team will visit you at home to complete the above mentioned data collection. In 
this case, we will need to collect your address and postal code solely for travel purposes. 
Your address and postal code will not be used for data analysis.         
Confidentiality 
The information collected will be used for research purposes only, and neither your name 
nor information which could identify you will be used in any publication or presentation of 
the study results.  We will look in your patient records from the hospital including your 
personal health information and we will collect only the information we need for this study.  
With your consent, we will be contacting your primary physician to obtain any existing 
blood work test results on file. All information collected for the study will be kept 
confidential.  All consent forms will be kept in a locked cabinet file owned by Dr. Marco 
Mura at Victoria Hospital in London, ON. Study data will be destroyed after 5 years.  
Risks & Benefits 
There are no foreseen risks to participating in this study. The only inconvenience 
experienced will be that will be meeting with a dietitian to discuss your weight history, and 
to talk about what you have eaten in the last 24 hours and to ask you to record what you 
eat for 3 days.  We will review with you how to complete this and will provide you with the 
forms to use to record your food intake. The benefit to the participant is that their future 
nutrition care interventions may be better directed. 
 
Voluntary Participation 
Participation in this study is voluntary. You may refuse to participate, refuse to answer any 
questions, complete any portion of the study or withdraw from the study at any time with 
no effect on your medical care.  Should you choose not to participate any information about 
your study results will not be used.  
You will not be compensated for your time should you choose to participate.  
 
Questions 
If you have any questions about the conduct of this study or your rights as a research 
participant you may contact the Office of Research Ethics, Western University at 519-661-
3036 or ethics@uwo.ca. If you have any questions about this study, please contact the 
principal investigator, Dr. Janet Madill, RD, 1285 Western Road, Brescia University College, 
London N6G 1H2, 519-432-8353 extension 28240, jmadill@uwo.ca, or the research 
associate, Sylvia Rinaldi, at srinaldi@uwo.ca/sylvia.rinaldi@lhsc.on.ca.   
 
This letter is yours to keep for future reference.
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NUTRITIONAL STATUS OF PATIENTS WITH INTERSTITIAL LUNG 
DISEASE: A CROSS-SECTIONAL STUDY 
 
Dr. Janet Madill, Professor of Foods and Nutrition 




I have read the Letter of Information, have had the nature of the study 
explained to me and I agree to participate. All questions have been 




Name (please print): 
 
 






























Study #:___________                                                                           Date:_____________    

























Appetite Good / Fair / Poor 
BMI   
 Duration 
Nausea  
Weight Δ  
↑    ↓      
Intentional/Unintentional 
Vomiting  
6 months  Diarrhea  
2 weeks  Constipation  
























Tim e Spent  
Walking for 
at least 10 
minutes 
Days  





















□ Diabetes: Type 1/Type 2       Insulin: Y/N     Oral meds: Y/N   Neuropathy: 
_________ 
□ CVD:  HTN / ↑cholesterol / ↑TG / stroke / MI 
□ Liver Disease 
□ Renal Disease 
□ Gastroesophageal reflux disease/Hiatal Hernia 
□ Skin Breakdown/Wound Healing: Location: ________________________ 
□ Cancer: _________________ 










Pack years:                                         Years Quit: 
 
Labs (Date: _______________) 3D-FIR given: mail / email / fax / call x 2 weeks 
  Calcium                  
Vitamin D  
Study #:___________                                                                           Date:_____________    
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Subjective Global Assessment Scoring Sheet 
PART 1: MEDICAL HISTORY 
1. WEIGHT CHANGE 
SGA Score 
A B C 
A. Overall change in past 6 months: ___________________ kg / lb    
B. Percent change: ______ gain - <5% loss 
                           ______ 5 – 10% loss 
                           ______ >10% loss 
   
   
   
C. Change in past 2 weeks: ______ increase 
                                         ______ no change; normal weight 
                                         ______ no change; below usual weight  
                                         ______ decrease 
   
   
   
   
2. DIETARY INTAKE 
                            ______ no change, adequate 
                            ______ no change, inadequate 
                            ______ change (duration________________) 
   
   
   
   
Current intake: ______ suboptimal or ______ full fluid  
                         ______ hypocaloric liquid or ______ starvation 
______ Intake borderline; increasing 
______ Intake borderline; decreasing 
______ Intake poor; no change 
______ Intake poor; increasing 
______ Intake poor; decreasing 
   
   
   
   
   
   
   
3. GASTROINTESTINAL SYMPTOMS (persisting for > 2 weeks)    
Frequency: _________ nausea; _________ vomiting;  
                   _________ diarrhea; _________ constipation;  
                   _________ anorexia; _________  chewing/swallowing issues 
______ None 
______ Some (daily > 2weeks) 
______ All (daily > 2weeks) 
   
   
   
   
   
   
4. FUNCTIONAL IMPAIRMENT (nutritionally related) 
A. Overall impairment: ______ none 
                                ______ moderate (difficulty ambulating/ ADLs) 
                                ______ severe (bed/chair-ridden) 
B. Change in past 2 weeks: ______ improved 
                                         ______ no change 
                                         ______ regressed+ 
C.  
   
   
   
   
   
   
   
PART 2: PHYSICAL EXAMINATION 
Evidence of: Loss of subcutaneous fat 
                       Muscle wasting 
                       Edema 
                       Ascites  
   
   
   
   
   
PART 3: SGA RATING (check one) 
Well-Nourished:  Mildy-Moderately Malnourished: Severely 
Malnourished: 
□A □A- □B+ □B □B- □C+ □C- 
Study # : ________________                                                                   Date:  ______________         
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BodyStat Output (Test # __________)  
If possible, the electrodes should be placed on the right side of the body.  
Electrodes have been placed on:  □ RIGHT □ LEFT 
Indicate the logistical circumstances for electrodes be placed on the left side: 
______________________________________________________________  
(Note: Electrode placement should be on the SAME SIDE of the body as was used for the first 
measurement for subsequent measurements) 
Presence of pacemaker or metal in body: □ YES □ NO 
Is the patient lying flat?  □ YES □ NO  
If supine position is not possible, indicate the position when measurement is being taken 
_______________________  
(Note: If supine position is not possible, head of bed should be elevated to 30 degrees) 
Treat results with caution? □ YES □ NO 
Measure Value 
Height (cm)  





Lean body mass (kg)  





Extracellular water   
Intracellular water  





Wellness Marker   
Impedance 5 kHz 50 kHz 
Resistance  
Reactance  
Phase Angle  
 
Study # : ________________                                                                   Date:  ______________         
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Quadricep Muscle Layer Thickness Ultrasound Output    
(Researcher initials: __________) 
 Length (cm)  QMLT at Min Pressure (cm) 
 Right Left  Right Left 
ASIS to top of 
patella 
  Mid-point 
  
Midpoint distance 
from top of patella 
  2/3 point 
  
1/3 distance from 
top of patella 




Dominant hand: □ RIGHT □ LEFT   Other Considerations:_________________________ 
Left Hand Right Hand 
Test 1  Test 1  
Test 2  Test 2  
Test 3  Test 3  
Mean  Mean  
Pop. mean +/- SD  Pop. mean +/- SD  
 













       
 
Pulmonary function tests (Date:________________) 
 Predicted Actual % Predicted 
FEV1    
DLCO    
FVC    
 
Checklist:  




□ 24-hr Recall  
□ 3D-FIR given to participant  
(call x 2 weeks / email / mail / fax) 























Bioelectrical Impedance Analysis Protocol 
Adapted from the Body Composition Procedures Manual 
 (National Health Nutrition and Examination Survery 2000) 
This dissertation research used the BodyStat® 1500MDD device which estimates body 
composition using multifrequency bioelectrical impedance analysis.  
 
Figure 5 BodyStat ® 1500MD device 
Protocol 
Body Position 
Position participant in a supine position (lying flat) with legs separated and arms away 
from the trunk of the body (See Figure 6). If the participant is unable to keep their arms 
and legs adequately separated, a towel can be placed between the legs or between the arm 
and the trunk to ensure separation through the test.  
 
Figure 6 Proper body position 
 
Legs separated 
Arms not  






Electrode Placement  
Two electrode pads are placed on each of the right hand and foot (Figure 7). Clean the 
surface of the hand and foot with an alcohol swap before placement of the electrode pads. 
Right Hand: Place one pad on the surface of the top of the hand just before the knuckles. 
Place the second electrode sticker on the surface of the wrist along the midline of the 
ulnar bone (prominent bone on the outer side of the wrist). 
Right Foot: Place one pad on the surface of the top of the foot just before the knuckles of 
the toes. Place the second electrode sticker on the surface of the ankle along the midline 
of the lateral malleoli (prominent bone on the outer side of the ankle). 
Connect electrode leads (cords) to the BodyStat® device. Connect the black electrode 
lead to the electrode pad on the wrist/ankle using the alligator clip and connect the red 
electrode lead to the electrode pads closest to the fingers/toes using the alligator clip. 
 
Figure 7 Electrode placement on right hand and foot (BodyStat 2017). 
Data Input 
Input the participants sex, age, height and weight into the device. Once the participant is 
in correct position and electrodes are properly set up, the test can be run. This should take 
approximately 5 seconds. Test results will appear on the screen. The test is complete and 















































Computed Tomography Scan Study Proposal 
 
Interstitial lung disease (ILD) is a group of disorders that involve irritation and swelling 
of the tissue lining the lungs. Patients with ILD make up 26-44% of those that receive a 
lung transplant in Canada. A component of lung candidacy is patient body mass index, 
and often patients are required to lose weight in order to be listed for lung transplant. 
However, there is little information known about nutritional concerns of this patient 
population through disease progression or leading up to potential lung transplant. Thus, 
better understanding nutritional issues has the potential to impact patients’ long-term 
outcomes. This study aims to address the question, is the amount of muscle mass at 
diagnosis and through disease progression an outcome indicator in ILD? The primary 
objective is to determine the prevalence of sarcopenia, or low muscle mass, and 
sarcopenic obesity in patients with ILD at diagnosis and through disease progression. The 
secondary objective is to examine if sarcopenia and sarcopenic obesity are associated 
with survival time. The tertiary objective is to determine if body fat and lean muscle 
mass measured by computed tomography imaging, in select cases, is correlated with 
measures of body composition assessed using BIA. The research team will review patient 
files from a previous pilot study. Previously completed CT-scans will be used to measure 
the amount of skeletal mass at various stages of ILD beginning at diagnosis. In select 
cases, muscle mass determined using CT-scans will be used to validate previously 
completed body composition measures via bioelectrical impedance analysis from the 
pilot study. This research addresses a large research potential regarding computed 
tomography imaging within the ILD/IPF patient population in the literature. As minimal 
information is known about the nutritional status of ILD patients, new and novel research 
is needed to understand this vulnerable patient population. It is hoped that the knowledge 
gained from the study will help health professionals proactively provide best nutrition 
































*Included above is the initial ethics approval notice, however, since this was obtained, 
multiple amendments applications have been made and approved to increase sample size, 




































Commencement of study  
• Ethics approval was received from The University of 
Western Ontario Research Ethics Board for Health Sciences 
Research Involving Human Subjects (HSREB) on 
September 25th, 2013.  
October 2013  Recruitment of subjects and data collection  
 
May 2016  Additional study parameters added  
• hand-grip strength 
• quadricep muscle layer thickness via ultrasound technology 
January 2019  Data analysis  
• Participants recruited up until January 2017 (to allow for 2-
year survival time) used in data analysis  
• Recruitment on-going related to hand-grip strength and 




During clinic visit 
• Bioelectrical impedance analysis* 
• Subjective global assessment* 
• 24-hr recall  
• Handgrip strength and quadricep muscle layer thickness (added May 2016) 
 
Outside of clinic visit 
• 3-day food intake record (obtained by phone, e-mail, mail or fax) 
 




• Specific diagnosis* 
• Time from diagnosis* 
• Pulmonary function tests* 
• 6-min walk distance* 
• Medications* 
• Comorbidities  
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Sept 2011 – Apr 2013 
Brescia University College at Western University, London ON 
  
BSc Honours Biochemistry  
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Sept 2007 – Apr 2011 
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• Member of the College of Dietitians of Ontario (Registration # 14090) 
 
RESEARCH AND ACADEMIC INTERESTS 
• nutritional assessment 
• interstitial lung disease (ILD) 
• pulmonary hypertension (PH) 
• body composition 
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• phase angle as a nutritional indicator 
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June 2017 $10,000 
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